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                                             1. INTRODUCTION 
 
 
Oral route of administration is the most important method of administering 
drugs for systemic effects. Many pharmaceutical dosages are administered in the form 
of   tablets, hard gelatin capsules, granules, powders, and liquids. Many patients, 
particularly pediatric and geriatric and bed ridden patients have difficulty in swallowing 
or chewing solid dosage forms. This problem is also applicable to active working or 
travelling people who do not have ready access to water. Recent advances in novel drug 
delivery systems (NDDS) aim to develop fast dissolving /disintegrating tablets to 
improve patience compliance. Dispersible tablets (DTs) Dissolve or disintegrate in 
saliva within a minute without the need of water or chewing. 
Advantages of dispersible tablets include convenience of administration, patient 
compliance, rapid onset of action, increased bioavailability, accurate dosing as 
compared to liquids, good stability, ability to provide advantages of liquid medication 
in the form of solid preparation, ideal for paediatric anti geriatric patient and rapid 
dissolution/absorption of the drug. Some drugs are absorbed from the oral cavity 
(mouth, pharynx and esophagus) as the saliva passes down into the stomach. In such 
cases, bioavailability of drug is significantly greater than those observed from 
conventional tablet dosage form. Dispersible tablet also beneficial for schizophrenic, 
parkinsonism or developmentally disabled patients with persistent nausea, those with 
conditions of motion  sickness, sudden episodes of allergic attack or coughing, and  
patients who do not have ready access to water 
The various technologies used to prepare DTs include conventional methods 
like direct compression, wet granulation, and moulding, spray drying, freeze drying and 
sublimation. Direct compression represents a simple and cost effective tablet 
manufacturing technique. The basic approach used in the development of the 
dispersible tablets is the use of Superdisintegrants. Superdisintegrants facilitate the 
break upon disintegration of tablet content into smaller particles that can dissolve more 
rapidly than conventional dosage form. The commonly used superdisintegrants are 
Croscarmellosesodium, Crospovidone, Kollidon CLM and sodium Starch glycolate. 
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1.1 TABLETS (1): 
Tablets may be defined as solid pharmaceutical dosage forms containing drug 
substances with or without suitable diluents and prepared either by compression or 
molding methods. They have been in widespread use since the latter part of the19th 
centuries and their popularity continues. The term compressed tablet is believed to have 
been first used by ‘John Wyeth and Brother of Philadelphian’ during the same period 
moulded tablets were introduced to be used as hypodermic tablets for injections. 
Tablets remain popular as a dosage form because of the advantages, afforded both to 
the manufacturer [e.g. simplicity & economy of preparation, stability and convenience 
in packing, shipping, and dispensing] and the patient [e.g. accuracy of dosage, 
compactness, and post ability, blandness of taste and ease of administration]. 
Although tablets are more frequently discoid in shape, they also may be round, 
oval, oblong, cylindrical or triangular. They may differ greatly in size and weight 
depending on the amount of drug substance present and the intended method of 
administration. 
1.2 ADVANTAGES OF TABLETS 
•   They are easy to administer. 
•   They are a unit dosage form, and they offer the greater capabilities of 
all oral dosage forms for the greatest dose precision and the least content 
variability. 
•   Their cost is lowest of all oral dosage forms. 
• They are the lightest and most compact of all oral dosage forms. 
• Product identification is potentially the simplest and cheapest, requiring 
no additional processing steps when employing an embossed or 
monogrammed punch face. 
• They are in general the easiest and cheapest to package and ship of all 
oral dosage forms. 
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• They may provide the greatest ease of swallowing with the least 
tendency for "hang-up" above the stomach. Especially when coated, 
provided that tablet   disintegration is not excessively rapid. 
1.2 DISADVANTAGES OF TABLETS 
• Some drugs resist compression into dense compacts, owing to their 
amorphous nature or flocculent, low-density character. 
• Drugs with poor wetting, slow dissolution properties, intermediate to 
large dosages, optimum absorption high in the gastrointestinal tract, or 
any combination of these features may be difficult or impossible to 
formulate and manufacture as a tablet that will still provide adequate or 
full drug bioavailability. 
• Bitter tasting drugs, drugs with objectionable odour or drugs that are 
sensitive to oxygen or atmosphere moisture may require encapsulation 
or a special type of coating which may increase the cost of the finished 
tablets. 
1.3 PROPERTIES OF AN IDEAL TABLET 
 
• Tablet should be elegant having its own identity and free from defects 
such as Cracks, chips, contamination, discoloration etc. 
• It should have chemical and physical stability to maintain its physical 
integrity over time. 
• It should be capable to prevent any alteration in the chemical and 
physical Properties of medicinal agent(s). 
• It should be capable of withstanding the rigors of mechanical shocks 
encountered in its production, packaging, shipping and dispensing. 
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• An ideal tablet should be able to release the medicament(s) in body in 
predictable and reproducible manner 
1.5  IDEAL REQUIREMENTS OF TABLET DOSAGE FORM (2, 3, 4, 5) 
The objectives of design and manufacture of the compressed tablet is to deliver 
orally the correct amount of drug in proper form, at or over the proper time and in 
desired location. Beside the physical and chemical properties of medical agents 
formulated as a tablet, it should possess following characteristics. 
• Should be an elegant product having its own identity while free of 
defects such as chips, cracks, discoloration and contamination. 
• Should have sufficient strength to withstand mechanical stress during its 
production, packing, shipping and dispensing. 
• Should have the chemical and physical stability to maintain its physical 
attributes. 
• The tablet must be able to release the medicinal agents in a predictable 
and reproducible manner. 
1.6    1.TYPES OF TABLETS (3) 
                                                                      The route of administration or functions classifies tablets as: 
 
1. Tablet Ingested orally 
• Standard compressed tablets 
• Multiple compressed tablets 
a)  Compression-coated tablet 
b)  Layered tablet 
• Modified Release tablet 
• Delayed Release tablet 
• Targetted Release Tablet 
                             a) Floating tablet 
b) Colon targeted tablet 
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• Chewable tablet 
• Dispersible tablet 
2.  Tablet used in oral cavity 
•   Lozenges and Troches 
•   Sublingual tablet 
•   Buccal tablet 
•   Dental cones 
•   Mouth dissolving tablet 
3.  Tablets administered by other routes 
•  Vaginal tablet 
• Implants 
4.   Tablets used to prepare solution 
•  Effervescent tablet 
•  Hypodermic tablet 
•  Soluble tablets 
 
1.6 TABLETING TECHNIQUES 
1. COMPRESSION COATED TABLETS 
              Compression-coated tablets have two parts, internal core and 
surrounding coat. The core is small porous tablet and prepared on one turret. For 
preparing final tablet, a bigger die cavity in another turret is used in which first the coat 
material is filled and the core tablet is mechanically transferred. Again the remaining 
space is filled with coat material and finally compression force is applied. 
 
 
 
 
Figure 1: Cross-sectional view of Compression- Coated tablet 
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 This tablet readily lend itself  into a repeat action tablet as the outer layer 
provides the initial dose while the inner core release the drug later on. But when the 
core quickly releases the drug, entirely different blood level is achieved with the risk of 
over dose toxicity. To avoid immediate release of both of the layers, the core tablet may 
be coated with enteric polymer, so that it will not release the drug in stomach while, the 
first dose is added in outer coating. 
2.   LAYERED TABLET 
When two or more active pharmaceutical ingredients are needed to be 
administered simultaneously and if they are incompatible, the best option for the 
formulation pharmacist would be to formulate layered tablet. It consists of several 
different granulations that are compressed to form a single tablet composed of two or 
more layers and usually each layer is of different color to produce a distinctive looking 
tablet. Each layer is fed from separate feed frame with individual weight control. Thus 
each layer undergoes light compression. 
 
Figure 2: Cross-sectional view of Layered tablet 
3.  MODIFIED RELEASE TABLETS 
Modified release tablets are coated or uncoated tablets containing auxiliary 
substances or prepared by procedures that are designed to modify the rate at which the 
active ingredients are released. Modified release tablets include enteric coated tablets, 
prolonged release tablets and delayed release tablets. 
4.  DELAYED RELEASE TABLETS 
These are tablets that resist dissolution or disruption in the gastric field 
(stomach), but readily disintegrate in the intestinal fluid to release the drug, thus 
rendering them delayed release features. 
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5.  CHEWABLE TABLETS 
These are compressed tablets that are designed to be chewed rather than 
swallowed. It is a well-tolerated alternative to traditional pediatric drug formulations 
and offer significant advantages in children of two years of age and elder. 
6.  DISPERSIBLE TABLETS 
Dispersible tablets are uncoated or film coated tablets that produce dispersion in 
an aqueous solution in less than one minute to form a smooth suspension without any 
coarse lumps. They can be prepared by using a simple formulation  containing a single 
disintegrating agent without employing specific combination of Disintegrant, gum, and 
etc. 
7.  MOUTH DISSOLVING TABLETS 
Mouth dissolving tablets are also known as orally disintegrating tablets or oro 
dispersible tablets. The Food and Drug Administration’s (FDA) definition of an orally 
disintegrating tablet (ODT) is “A solid dosage form containing medicinal substances 
which disintegrates rapidly, usually within a matter of seconds, when placed upon the 
tongue.” The dissolution test is too rigorous for orally disintegrating tablets due to their 
fast DT, ideally less than 30 seconds. Mouth dissolving tablets dissolve rapidly in 
saliva without the need of water. In certain cases, major claim of Mouth dissolving 
tablets is faster C max compared to traditional tablets. 
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CLASSIFICATION OF TABLETS 
 
                 
Fig 3:  CLASSIFICATION OF TABLETS 
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1.8  EXCIPIENTS USED FOR PREPARING OF TABLET (3, 5) 
  
 Excipients balance the properties of the actives in the release of dosage forms. 
This demands a thorough understanding of the chemistry of these excipients to prevent 
interaction with the actives. Determining the cost of these ingredients is another issue 
that needs to be addressed by formulators. The role of excipients is important in the 
formulation of fast-melting tablets. These inactive food-grade ingredients, when 
incorporated in the formulation, impart the desired organoleptic properties and product 
efficacy. Excipients are general and can be used for a broad range of actives, except 
some actives that require masking agents. 
 
BULKING MATERIALS 
     Bulking materials are significant in the formulation of fast-melting tablets. The 
material contributes functions of a diluent, filler and cost reducer. Bulking agents 
improve the textural characteristics that in turn enhance the disintegration in the mouth, 
besides; adding bulk also reduces the concentration of the active in the composition. 
The recommended  bulking agents for this delivery system should be more sugar-based 
such as mannitol,  polydextrose, lactitol, DCL (direct compressible lactose) and starch  
hydrolystate for higher aqueous solubility and good sensory perception. Mannitol in 
particular has high aqueous solubility and good sensory perception. Bulking agents are 
added in the range of 10 percent to about 90 percent by weight of the final composition. 
 
EMULSIFYING AGENTS 
       Emulsifying agents are important excipients for formulating immediate release 
tablets they aid in rapid disintegration and drug release. In addition, incorporating 
emulsifying agents is useful in stabilizing the immiscible blends and enhancing 
bioavailability. A wide range of emulsifiers is recommended for fast-tablet formulation, 
including alkyl sulfates, propylene glycol esters, lecithin, sucrose esters and others. 
These agents can be incorporated in the range of 0.05 percent to about 15 percent by 
weight of the final composition. 
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LUBRICANTS 
      Lubricants, though not essential excipients, can further assist in making these 
tablets more palatable after they disintegrate in the mouth. Lubricants remove grittiness 
and assist in the drug transport mechanism from the mouth down into the stomach. 
FLAVORS AND SWEETENERS 
 Flavors and taste-masking agents make the products more palatable and 
pleasing for patients. The addition of these ingredients assists in overcoming bitterness 
and undesirable tastes of some active ingredients. Both natural and synthetic flavors 
can be used to improve the organoleptic characteristic of fast-melting tablets. 
Formulators can choose from a wide range of sweeteners including sugar, dextrose and 
fructose, as well as non-nutritive sweeteners such as aspartame, sodium saccharin, 
sugar alcohols and sucralose. The addition of sweeteners contributes a pleasant taste as 
well as bulk to the composition. 
SUPER DISINTEGRANTS (6, 7) 
 A disintegrant is an excipient, which is added to a tablet or capsule blend to aid 
in the breakup of the compacted mass when it is put into a fluid environment. 
ADVANTAGES 
            1. Effective in lower concentrations 
            2. Less effect on compressibility and flow ability 
 3. More effective intra granularly 
 
SOME SUPER DISINTEGRANTS ARE 
 
1)  Sodium Starch Glycol ate (Explotab, primo gel) used in concentration of 2-8 % 
& optimum is 4%. 
 
 MECHANISM OF ACTION: Rapid and extensive swelling with minimal 
gelling. Microcrystalline cellulose (Synonym: Avicel, celex) used in concentration of 2-
15% of tablet weight. And Water wicking 
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2)  Cross-linked Povidone (crospovidone) (Koll done) used in concentration of   2-
5% of weight of tablet. Completely insoluble in water. 
 MECHANISM OF ACTION: Water wicking, swelling and possibly some 
deformation recovery. Rapidly disperses and swells in water, but does not gel even 
after prolonged exposure. Greatest rate of swelling compared to other disintegrants. 
Greater surface area to volume ratio than other disintegrants. 
3)  Low-substituted hydroxyl propyl cellulose, which is insoluble in water. Rapidly 
swells in water. Grades LH-11 and LH-21 exhibit the greatest degree of 
swelling. Certain grades can also provide some binding properties while 
retaining disintegration Capacity. Recommended concentration 1-5% 
4)  Cross linked carboxy methyl cellulose sodium (i.e. Ac-Di-sol) Croscarmellose 
sodium: 
 MECHANISM OF ACTION: Wicking due to fibrous structure, swelling with 
minimal gelling. Effective Concentrations: 1-3% Direct Compression, 2-4% Wet 
Granulation 
GAS PRODUCING DISINTEGRANTS 
 Gas producing disintegrants are used especially where extra rapid disintegration 
or readily soluble formulation is required. They have also been found of value when 
poor disintegration characteristics have resisted other methods of improvement. Care 
should be taken during tableting, particularly on moisture level. Composition is based 
upon the same principles as those used for effervescent tablets, the most common being 
mixtures of citric & tartaric acids plus carbonates or bicarbonates. In many instances 
lower concentration can be used with gas producing disintegrants than are required by 
other disintegrating agents. Certain peroxides that release oxygen have been tried, but 
they do not perform as well as those releasing carbon dioxide. 
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1.9. GENERAL STEPS FOR TABLET MAKING 
 
 Granulation Milling 
 Drying 
 Blending 
 Compression 
 Coating 
 
1. GRANULATION (8) 
Granulation is one of the most important unit operations in the production of 
pharmaceutical oral dosage forms. Granulation is defined as an operation by which 
particles are agglomerated using binder solution or slugging to form granules. The main 
purpose of granulation is to improve powder properties by an increase in particle size 
owing to agglomeration of fine raw materials. The general purposes of granulation are 
to increase the apparent bulk density, enhance the flowability, modify the dissolution 
rate, lower the dust ability and enhance the stability 
The characteristics of granulations are of interest in the formulation and 
development as well as in production of solid dosage forms because they affect the 
performance properties of the final product, such as disintegration and dissolution rate, 
tablet hardness, friability, and capping tendency. A poorly reproducible granulation 
process may give rise to difficulties and time-consuming troubleshooting in the 
production line. The characteristics of particulate matter in general can be divided into 
basic material characteristics: fundamental characteristics and derived bulk 
characteristics. The granulation characteristics evaluated by the development 
pharmacist are the derived bulk properties, that is, the properties related to subsequent 
processing, such as packing and flow properties, tablet compression, disintegration and 
dissolution properties. Some fundamental characteristics should also be involved in the 
development phase. Such characteristics include assessment and specification of 
granule structure and porosity, size distribution and friability, all of which may have a 
significant effect on the subsequent processing and the final product quality. 
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Three principle methods of developing powders for tablet making are: 
1) Direct compression 
2) Dry granulation 
3) Wet granulation 
 
2.  DIRECT COMPRESSION (9) 
Powders that can be mixed well do not require granulation and can be 
compressed into tablets through direct compression. In direct compression, a 
compressible vehicle is blended with the medicinal agent, lubricant and a disintegrate, 
and then the blend is compressed. The term direct compression is used to define the 
process by which tablets are compressed directly from powder blends of the active 
ingredients and suitable excipients (including fillers, disintegrant and lubricants), which 
will flow uniformly into a die cavity and form into a firm compact. No pretreatment of 
the powder blends by wet or dry granulation procedures is necessary. Mainly, Lactose 
monohydrate, anhydrous lactose, Dextrose, Compressible sugar, Micro crystalline 
cellulose, Starch, Unmilled Dicalcium phosphate etc. are used as suitable excipients for 
direct compression methods. 
 
ADVANTAGES OF DIRECT COMPRESSION 
• Economic 
• It eliminates heat and moisture 
• Prime particle dissociation 
• Stability 
• Particle size uniformity 
 
DISADVANTAGES OF DIRECT COMPRESSION 
• Although  there are many significant advantages of direct compression over 
granulation, there exist important limitations: 
• Uniform blending and prevention of unblending of low – dose drugs. 
• Fillers often used are costlier than those used in granulation. 
• Physical properties and functional specifications are more critical; properties of 
raw materials must be defined and carefully controlled. 
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• Dusting problems 
• More sensitive to lubricant softening and over mixing than granulation. 
 
3.  DRY GRANULATION 
 
Dry granulation is a technique in which materials used does not apparently 
assume any kind of liquid state. In dry granulation process, powder is densified 
between usually two counter-rotating rolls. This results in an (ideally) endless ribbon, 
which is subsequently fed into an external or integrated granulation (milling) unit, 
which mills the ribbons down to the desired granule size. 
 
DRY GRANULATION CAN BE USED AS ADVANTAGE IN THE 
FOLLOWING SITUATIONS 
• For moisture- sensitive and heat- sensitive materials. 
• For improved disintegration, since the powder particles are not bonded together 
by a binder. 
• For improved solubility, as with anhydrous soluble materials that tend to set 
them wet. 
• For improved blending, since there is no migration of active ingredients as 
might occur during the drying of a wet granulation. 
 
SOME OF THE DISADVANTAGES OF DRY GRANULATION ARE AS 
FOLLOWS 
 
• It requires a specialized heavy-duty tablet press to form the slug. 
• It does not permit uniform color distribution as can be achieved with wet 
granulation, where the die can be incorporated into the binder liquid. 
• A pressure roll press such as the Chilsonator cannot be used with insoluble 
drugs since this may retard the dissolution rate. 
• The process tends to create more dust than wet granulation, increasing the 
potential for cross-contamination. 
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TWO PROCESSES ARE USED FOR DRY GRANULATION: 
 
a) Compression granulation 
b) Roller compaction 
 
a) DRY GRANULATION BY COMPRESSION GRANULATION 
 
Compression granulation is a valuable technique in situation where the effective 
dose of a drug is too high for direct compression, and the drug is sensitive to heat, 
moisture or both. Example, many aspirin and vitamin formulations are prepared for 
tabletting by compression granulation involves the compaction of the components of a 
tablet formulation by means of a tablet press or specially designed machinery, followed 
by milling and screening prior to final compression into a tablet. 
 
b)  DRY GRANULATION BY ROLLER COMPACTION 
 
The basic concept of compaction is to force fine powders between two counter 
rotating rolls. As the volume decreases through the region of maximum pressure, the 
material is formed into a solid compact or sheet. Some of the factors controlling the 
compaction process are roll surface, diameter, peripheral speed, separating force or 
pressure capabilities, feed screw design and basic compaction characteristics of 
material being processed. On a large scale, dry granulation can also be performed on a 
specially designed machine called roller compactor. Roller compactor utilizes two 
rollers that revolve towards each other. Roller compactor compacted ribbon like 
material or large pieces called briquettes, which can then be screened or milled into a 
granulation suitable for compression into tablets. 
 
4.  WET GRANULATION 
 
Wet granulation is an important process in the formulation of solid dosage 
forms in the pharmaceutical industry. Wet granulation is used to improve flow, 
compressibility, bioavailability, and homogeneity of low dose blends, electrostatic 
properties of powders and stability of dosage forms. Granule formation and growth 
proceed because of effects of mobile-liquid bonding formed between the primary 
particles. During wet granulation the following material properties influence the 
granule formation and growth: 
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• Solubility of the particles in the binder liquid. 
• Contact angle of the binder liquid to the solids. 
• Mean particle size and size distribution of solids. 
• Particle shape and surface morphology. 
 
   A crude way of determining the end point is to press a portion of the mass in the 
palm of the hand, if the ball crumbles under moderate pressure; the mixer is ready for 
next step of wet screening. Certain important parameters to be monitored during wet 
granulation are dry mixing time, binder addition time, kneading time, impeller speed 
(RPM), chopper speed (RPM) and the quantity of product. 
 
Advantages of wet granulation: 
• Enhances fluidity and compatibility, suitable for high-dose drugs with poor flow 
and /or compatibility. 
• Reduces air entrapment and dustiness. 
• Provides for the addition of a liquid phase (wet granulation) suited to dispersion 
of low-dose drugs in solution to ensure content uniformity. 
• Enhances wettability of powders through hydrophilization (wet granulation). 
• Permits handling of powders without loss of blend quality. 
 
Disadvantages of wet granulation 
• Each unit process brings its own set of complications. 
• The large number of unit processes increases the chances of problems. 
• Potential adverse effects of temperature, time and rate of drying on drug stability   
and distribution during drying. 
• Overall, more costly than direct compression in terms of space, time and 
equipment required. 
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5. MILLING 
 
Milling is a mechanical process of reducing the particle size of solids. During 
milling process, the solubility of poorly soluble drugs increases due to the decrease in  
Particle size and resultant increase in the surface area. The principle of operation 
depends upon direct pressure, impact from a sharp blow, attrition or cutting. The most 
commonly used mills in pharmaceutical manufacturing are the rotary cutter, hammer 
mills, roller and fluid-energy mill. 
 
6.  DRYING 
 
A drying process is required in wet granulation to remove the solvent. Drying is 
used as a unit process in the preparation of granules, which can be dispensed in bulk or 
converted into tablets. Dried products are more stable than the moist ones, so drying is 
important in case of tablet manufacturing. Various equipments used for drying are: 
¾ Static-bed dryer 
¾ Moving-bed dryer 
¾ Fluidized-bed dryer 
 
7.  BLENDING 
 
Blending of powders is a process in which two or more dissimilar particulate 
solids are blended to give a random mix. A blending operation is required to mix the 
lubricants after drying of granulated particles. In most cases high degree of uniformity 
is essential for the final preparation. Blending mainly depends upon the properties of 
the powder, equipments used and the operating conditions. Most commonly used 
equipments for blending are Double-cone blender, V-blender, Ribbon blender, 
turbulent blend. 
 
8. COMPRESSION (9) 
  Compression is the process of applying pressure to a material. In 
pharmaceutical tabletting an appropriate volume of granules in a die cavity is 
compressed between an upper and a lower punch to consolidate the material into a 
single solid matrix, which is subsequently ejected from the die cavity as an intact tablet. 
Tablet compression machine are designed with the following basic component. 
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Hopper for holding and feeding granules to be compressed 
• Dies that define size and shape of tablets 
• Punches for compressing the granules into tablets 
• Cam track for guiding the movement of the punches 
• A feeding mechanism for moving granulation from the hopper  into the dies 
• The granules filled in volumetric basis are then compressed into tablets under suitable 
compaction force. 
 
The subsequent events that occur in the process of compression are: 
• Transitional repacking 
• Deformation at points of contact 
• Fragmentation or deformation 
• Bonding 
• Deformation of the solid body, 
• Decompression, 
• Ejection. 
 
    The process of compression has been described in terms of the relative volume (ratio of 
volume of the compressed mass to the volume of the mass at zero void) and applied pressure. 
The quotient of the applied force and the area of true contact is the applied deformation 
pressure at the areas of true contact. It has been stated that smaller particles yield larger areas of 
true contact and thus bond more strongly. Density, porosity, hardness, tensile strength, specific 
surface, disintegration and dissolution are the properties of tablets that are influenced by 
compression. 
 
1.10 MANUFACTURING PROBLEMS OF TABLETS (10) 
 
The defects in tablet are as follows: 
 
CAPPING 
 
The partial or complete separation of the top or bottom crowns of a tablet from 
the Main body of the tablet is termed as capping. 
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LAMINATION 
Lamination is the separation of a tablet into two more distinct layers. 
CHIPPING 
It is defined as the breakage of tablet edges. 
CRACKING 
Formation of small, fine cracks on the upper and lower central surface of tablets 
or Very rarely on the sidewall are termed as cracking. 
STICKING 
The partial or complete separation of the top or bottom crowns of a tablet from 
the main body of the tablet is termed as capping. 
MOTTLING 
An unequal distribution of color on a tablet with light or dark on the surface is 
termed as mottling. 
DOUBLE IMPRESSION 
It involves only those punches, which have a monogram or other engraving on 
them. Free rotation of either upper punch or lower punch during ejection of a tablet 
Causes double impression. 
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1.11  DISPERSIBLE TABLETS (11) 
DEFINITION 
Dispersible tablets are uncoated tablet that produce dispersion in an aqueous 
solution in less than 3 minute to form a smooth suspension without lumps. They can be 
prepared by following ways 
    1.     Simple formulation containing a single disintegrating agent without specific 
combination of disintegrant, gum etc. 
1.12  DESIRED CHARACTERISTICS OF DISPERSIBLE  
TABLET: 
1]  Bioavailability 
2]  Rapid drug therapy intervention is possible 
3]  Sufficient mechanical strength 
4]  Allow high drug loading 
5]  Rapid onset of therapeutic action 
6]  Good compatibility with development technology 
7]  Leaves no residue in mouth after oral administration 
8]  Stability 
9]  Conventional packaging and processing equipments allows the 
manufacturing of tablets at low cost 
10]  Be compatible with taste masking and other excipients 
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1.13  ADVANTAGES OF DISPERSIBLE TABLET 
1.  It can be administered to the patient who cannot swallow conventional 
dosage form such as bedridden patients, elderly and patient effected by 
renal failure and thus improves patient compliance. 
2.  It is suitable for bedridden, disabled, traveler and busy persons who does 
not contain water every time. 
3.  Good mouth feel property helps to mask the bitterness of medicines. 
4.  Rapid drug therapy intervention. 
5.  It provides rapid absorption of drugs and increased bioavailability 
6.  It allows high drug loading 
7.  No chewing needed. 
8.  The risk of suffocation during oral administration of conventional 
formulation due to physical obstructions is avoided and provides safety. 
1.14 DISADVANTAGES OF DISPERSIBLE TABLETS 
1.  It requires proper packaging for safety and stabilization of stable drugs. 
2.  It is hygroscopic in nature, so must kept in dry place 
3.  It shows the fragile, effervescence granules property 
4.  If not formulated properly, it may leave unpleasant taste in mouth. 
5.  Since the tablet having insufficient mechanical strength, so careful 
handling is required 
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1.15  TRADITIONAL TASTE MASKING TECHNOLOGIES IN 
DISPERSIBLE TABLETS 
1.  Taste masking by Ion-exchange Resins. 
2.   Taste masking by coating with Hydrophilic Vehicles. 
3.   Taste masking using Flavors and Sweeteners. 
 
1.16  FORMULATION ASPECTS IN DEVELOPING 
 DIPSERSIBLE TABLETS: 
Dispersible Tablets are formulated by several processes, which differ in their 
methodologies and vary in various properties such as: 
1.   Taste and mouth feel. 
2.   Mechanical strength of tablets 
3.   Drug dissolution in saliva. 
4.   Bio availability. 
5.   Stability. 
6.   Swallowability. 
 
CHALLENGES IN FORMULATING ORAL DISINTEGRATING 
TABLETS: 
1.  MECHANICAL STRENGTH: 
In order to swallow DTs to disintegrate in the oral cavity, they are either made 
of porous or soft molded matrices, which makes tablet friable and difficult to handle 
and hence requires peel-off blister packing which increases its cost 
2. PALATABILITY 
Since most drugs are unpalatable, orally disintegrating drug delivery system 
contains medicament in taste masked form .It dissolves in patient oral cavity, thus 
release the active ingredient which comes in contact with the taste buds. 
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3.  AQUEOUS SOLUBILITY 
Water soluble drugs pose various formulation challenges results in freezing 
point depression and formation of glassy solids that may collapse upon drying. Such 
collapse can be prevented by using various matrix forming excipients like mannitol. 
4.  AMOUNT OF DRUG 
The application for technologies used for DTs is limited by the amount of drug 
into each unit dose. The drug dose must be lower than 400mg for insoluble drugs and 
60mg for soluble drugs. 
5.  SIZE OF TABLET 
The easiest size of tablet to swallow is 7-8mm while the easiest size to handle is 
8mm.Therefore, tablet size that is easy to handle and easy to take is difficult to achieve. 
6.  HYGROSCOPICITY 
Many orally disintegrating dosage forms are hygroscopic in nature.  Hence they 
need protection from humidity. 
MECHANISM OF DISPERSIBLE TABLETS 
It involves the following mechanism – 
• Incorporation of an appropriate disintegrating agent in the tablet            
formulation. 
• For rapid disintegration and dissolution of the tablet, water must quickly enter      
into tablet matrix. 
• Tablet is broken down into smaller particles. 
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1.17 EXCIPIENTS USED FOR PREPARATION OF DISPERSIBLE 
TABLET 
1)  SUPER DISINTEGRATES- 
It increases the rate of disintegration and dissolution. For the success of                   
orally disintegrating tablet, the tablet having quick dissolving property which is 
achieved by super disintegrants. Examples are- Crospovidone, MCC, Sodium starch 
glycolate, CMC, Carboxy methyl cellulose and modified corn starch. 
2) SWEETENERS AND SUGAR BASED EXCIPIENTS- 
              Sugar based excipient act as bulking agents. They exhibit high aqueous 
solubility and sweetness and impart taste masking property. Examples are-
Aspartame, Sugar derivative, Dextrose, Fructose, Mannitol, Sorbitol, Maltose etc. 
3) FLAVORS- 
                   It increases patient compliance and acceptability. Examples are-Vanilla, 
Citrus oil, Fruit essence, Eucalyptus oil, Clove oil, Peppermint oil etc. 
4) SURFACE ACTIVE AGENTS- 
                It reduces interfacial tension and thus enhances solubilization of 
Dispersible tablets .Examples are-Sodium lauryl sulfate, Sodium doecyl sulfate, 
Polyoxyethylene sorbitan fatty acid esters, Polyoxyethylene steartes etc. 
5) BINDER- 
                It maintains integrity of dosage form. Examples are-PVP, Polyvinyl 
alchol, Hydroxy propyl methylcellulose. 
6) COLOUR- 
                 It enhances appearance and organoleptic properties of dosage form. 
Examples are-Sunset yellow, Red iron oxide, Amaranth. 
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7) LUBRICANTS- 
It helps reduces friction and wear by introducing a lubricating film. Examples 
are- Stearic acid, Magnesium stearate, Zinc stearte, Talc, Polyethylene glycol, 
Liquid paraffin, Colloidal silicon-di-oxide etc. 
8) FILLERS- 
It enhances bulk of dosage form. Examples are-Mannitol, Sorbitol, Xylitol, 
Calcium carbonate, Magnesium carbonate, Calcium sulfate, Magnesium trisilicate 
etc. 
 
1.18 TECHNIQUES USED FOR PREPARATION OF DT’s 
A) CONVENTIONAL TECHNIQUES: Various conventional techniques are 
available for preparation of DT’s are- 
1.   FREEZE DRYING:  
       It is a process in which water is sublimated from the product after freezing. In 
this heat sensitive drugs and biological are dried at low temperature that allows 
removal of water by sublimation. 
 2.     SUBLIMATION:  
   In these, inert solid ingredient that volatilized readily was added to other tablet 
ingredient and mixture is compressed into tablets. The volatile material was then 
removed by the process of sublimation. 
3. SPRAY-DRYING:  
  It produces very fine and highly porous powder. Tablets prepared from spray 
drying disintegrate within 20 sec when immersed in an aqueous medium. 
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4. MOLDING:  
   In these, water soluble ingredients are used to prepare molded tablets so that 
tablet dissolves rapidly. Molded tablets are very less compact then compressed 
tablets and exhibit porous structure for rapid dissolution. 
5. MASS-EXTRUSION:   
   It involves softening the active blends using the solvent mixture of water 
soluble PEG. The granules of bitter tasting drugs are coat by dried cylinders and 
hence masking their bitter taste. 
6. DISINTEGRATES ADDITION:  
   Because of   its easy implementation and cost effectiveness, it is a popular 
technique for formulating Dispersible Tablet. The basic principle involved is 
addition of super-disintegrants in optimum concentration. 
7. DIRECT COMPRESSION:  
  It is the easiest way of manufacturing tablets. It consists of a limiting number 
of processing steps, conventional equipments and commonly available excipients. 
Also it requires few unit operations as compared to wet granulation. 
 
B.  PATENTED TECHNOLOGIES: Various patented technologies available 
for preparation of ODT’s are- 
   1.  FLASHTAB TECHNOLOGY:  
             In these, tablets consists active ingredient in the form of micro crystals. 
It is conventional tableting technology. Pro grapharm laboratories have patented 
the flash tab technology. 
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   2.       WOW TAB TECHNOLOGY:  
It involves adequate dissolution rate and hardness .It is patented by 
“Yamanouchi Pharmaceuticals Co”. Wow means without water. 
    3.        FLASH DOSE TECHNOLOGY:  
It requires greater surface area for dissolution. Flash dose tablets consist 
of self binding shear form matrix termed as “floss”. It has been patented by 
“Fuisz”. 
   4.  DURASOLV TECHNOLOGY:  
             It is a patented technology of “CIMA” labs. It consists of drug, fillers 
and lubricant. It requires low amount of active ingredient. 
   5.  ZYDIS TECHNOLOGY:  
             It involves quick dissolution, increased bioavailability and self-
preserving. It involves softening the active blends using the mixture of 
methanol and polyethylene glycol. 
   6.  ORASOLV TECHNOLOGY:  
             It is patented technology of “CIMA” labs. It involves quick dissolution 
and taste masking of active ingredient. 
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 2.  LITERATURE REVIEW 
 
 
AROHI VALERA. et.al, (11) The present work is aimed to develop a stable 
formulation of preferred combination of two antibiotics -Amoxicillin and Clavulanic 
acid to overcome packaging instability resulting in to swelling of blister pack due to 
their interaction causing gas generation. Amoxicillin and Clavulanic acid dispersible 
tablets were prepared by dry granulation method using different superdisintegrants i.e. 
Croscarmellose, Crospovidone and Sodium Starch Glycolate. 15°C temperature and 
20%RH humidity were throughout maintained. Aspartame as a sweetener and 
pineapple flavor were used to increase palatability. The prepared tablets were evaluated 
for hardness, friability, Disintegration time and Wetting time and in vitro drug release. 
Analytical estimation was done by HPLC. Amoxicillin and Clavulanic acid dispersible 
tablets were found to be of good quality fulfilling all the requirements for tablets. The 
results indicated that concentration of Crospovidone, Croscarmellose sodium, Sodium 
starch glycolate significantly affected. Croscarmellose Sodium showed least friability, 
disintegration time as compared to batches prepared from Sodium starch glycolate and 
Crospovidone Amoxicillin and Clavulanic acid dispersible tablets were successfully 
formulated by dry granulation technique with improved patient compliance & 
immediate onset of action. 
   ANAB FATIMA SHEIKH, et.al,(12) The combination of amoxicillin and 
clavulanic acid is a widely used oral combination of antibiotic consisting of 
semisynthetic amino penicillin amoxicillin and a beta-lactamase inhibitor i.e. 
clavulanate potassium (potassium salt of clavulanic acid). A simple, rapid, and cost 
effective reverse phase high performance liquid chromatography method has been 
developed with greater precision and accuracy using Hibar-Purospher star reverse 
phase(RP-18e) column(4.6 x 250 mm, 5µm) for simultaneous determination of  
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amoxicillin trihydrate and clavulanate potassium in pharmaceutical formulations. The 
separation was achieved in isocratic mode using buffer-methanol in the ratio of 90:10 
v/v with pH 3 (adjusted with O-phosphoric acid) as mobile phase at flow rate of 1.3 
ml/min. The detection was made at 235 nm. The retention time of clavulanate 
potassium and amoxicillin trihydrate were 4.7 and 10.0 minutes respectively. The limit 
of detection was 0.015 µg/ml for amoxicillin and 0.12 µg/ml for clavulanate potassium. 
GAUTHAM KUMAR, et.al,(13): In present study , the fast dissolving tablets of  
Amoxicillin Trihydrate were prepared by direct compression technique using 
microcrystalline cellulose (MCC) as direct compressible diluents. Sodium Starch 
Glycolate(SSG) and croscarmellose sodium(CCS) used as synthetic disintegrants. The 
Swelling indices of the superdisintegrants were also compared.  Among both the 
superdisintegrants croscarmellose sodium shows the highest swelling index.  Theblends 
showed satisfactorily flow properties. Eight formulation were prepared using  different 
concentrations of superdisintegrants and were investigated for their effect on the 
disintegration time and dissolution rate of the tablets.  Tablets were also evaluated for 
weight variation, hardness, thickness friability and drug content. All the tablets 
exhibited acceptable pharmaco-technical properties. Tablets prepared with the blend of 
CCS(60mg) exhibited quicker disintegration. According to the present study, it was 
found that tablets of batch F8 (Blend containing CCS 60mg) showed better 
disintegrating property as well as % drug release (99.78% within 25 min) than the most 
widely used synthetic disintegrants like SSG in the formulation of FDTS. 
         SAURABH SHARMA. et.al, (14) Orodispersible tablets emerged from the desire 
to provide patient with conventional mean of taking their medication. Difficulty in 
swallowing (Dysphagia) is a common problem of all age groups, especially elderly and 
peadetrics because of pshycological change s associated with the group of patients. 
Lornoxicam is a non-steroidal anti inflammatory drug with extremely potent anti-
inflammatory and analgesic activity. Lornoxicam shows bitter taste and distinct pH-
dependent solubility characterized by very poor solubility in acidic condition present in 
the stomach. Therefore in present study, Lornoxicam taste masked orodispersible tablet 
was prepared by direct compression method and optimized the effect of sodium starch 
glycolate as superdisintegrant and camphor as sublimizing agent on disintegration of 
tablet with the help of surface response plot, counter plot, Box-Cox plot for power 
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transformation selected factorial method design for analysis of variance were calculated 
by using 32  Full Factorial design –Expert  8.0.7.1 Trial versions.  Orodispersible tablet 
batches  were prepared and evaluated for pre-compression parameters, post 
compression parameters and then characterized by differential scanning calorimetry 
(DSC), powder  X-ray diffraction (PXRD), Fourier  transform  infrared (FTIR) and in 
vitro release study of  all batches from F1-F8 was carried out in Ph 1.2 at 37ºC + 0.5 °C 
and shows maximum drug release in 105 min. 
 NWOKOYE PEACE, et.al, (15) Oral suspensions of antibiotics are mainly 
available as dry powders for reconstitution. Many reconstituted antibiotic suspension is 
to be kept refrigerated in order to get the optimal benefit from the drug. However, many 
patients do not keep to the specified storage conditions for different reasons like no 
refrigerator and irregular power supply that may result in various degrees of 
degradation of the product. Pharmacists are therefore challenged on how to counsel 
patients when there is no refrigeration or erratic power supply for refrigeration. This 
study investigated stability of amoxicillin-clavulanate potassium suspension in 
simulated in-home conditions of erratic power supply and no refrigeration. Amoxicilin 
clavulanate suspensions were reconstituted and stored in three different in-home 
storage conditions with temperature ranging between 5-29°C over a period of 10 days. 
Samples from the suspension were assayed using a validated HPLC method. 
Percentage concentrations of amoxicillin-clavulanate potassium were over 90% up to 
fifth day, degradation was extensive by seventh day with amoxicillin concentration 
falling below 80% in two conditions while clavulanate had values less than 70% in all 
the three conditions. Reconstituted amoxicillin clavunate potassium stored at room 
temperature (27-29°C) is stable for five days; use of reconstituted suspension that was 
not properly refrigerated after the fifth day should be discouraged. 
 MATHEW EBIN P SOVICHAN, et.al, (16) The objective of this work 
was to develop a formulation of Amoxicillin trihydrate dispersible tablets of 320mg in 
a low production value, using cheap Amoxicillin trihydrate raw materials available in 
the market, with direct compression or wet granulation method. Amoxicillin trihydrate 
is a semisynthetic antibiotic, an analogue of Ampicillin with a broad spectrum of 
bactericidal activity against gram +ve and gram ve organism. Dispersible tablets are 
uncoated or film coated tablets intended to be dispersed in water before administration 
31 
 
giving a homogeneous dispersion. The WHO prefers dispersible dosage form for the 
elderly and paediatric patients due to its ease in the administration. Amoxicillin 
trihydrate dispersible tablet was manufactured with the different disintegrants such as 
maize starch, crospovidone, croscarmellose, sodium starch glycolate, croscarmellose. 
The powder blend was evaluated for angle of repose, bulk density, tapped density, 
compressibility index and hausner’s ratio. After compression the tablets were subjected 
to weight variation, %drug content, buoyancy studies and in-vitro release studies. The 
wet granulation was excluded from the formulation due to its high cost if production, 
direct compression was selected due to its low cost and ease of production. The 
optimized formulation F10 had showed 99.11% of drug release in 40 min and 
disintegration of tablet was 25 seconds. The result of FTIR analysis of pure drug alone 
and drug with excipients there was not showed any physical and chemical interaction. 
F10 had undergone DTA, which shows the thermal stability of the formulation. The 
stability studies of optimized formulation F10 at 30 C / 65%RH, 40 C / 75%RH did not 
show any change in tested parameters and release. 
V.KALVIMOORTHI, et.al, (17) The antibiotics are available in many 
formulations in the market like solid dosage forms, liquid dosage forms, parental 
preparations etc. Amoxicillin clavulanate potassium acting as an antibiotic used in the 
treatment of patients with acquired pneumonia or acute bacterial sinusitis due to 
confirmed or suspected beta lactamase pathogens. It is an analog derived from the basic 
penicillin nucleus, 6-aminopencillanic acid. Totally nine formulations were made with 
different concentrations of coating polymers such as ethyl cellulose, hypromellose, 
opadry white and other ingredients were used in the same concentrations. Amoxicillin 
clavunate potassium tablets (cores) were prepared by direct compression method and 
coating of polymer to the tablets was done using pan coating. Tablets were evaluated 
for thickness, weight variation, hardness, friability, in – vitro dispersion time, 
disintegration time and dissolution study. Tablets shows uniform weight, hardness and 
friability data indicates good mechanical resistance of the tablets. Prepared tablets were 
evaluated for the disintegration test; all the tablets were disintegrated between 12 to 
14th minute. The formulation F6 shows best disintegration time. The prepared 
formulations (F1 to F9) were subjected for dissolution studies. Among all the 
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formulations F6 shows better dissolution profile of 104.7% and 104.2 % drug release at 
30th minute. This value is better when compared even with marketed formulation. 
SELLAPPAN VELMURUGAN. et.al, (18) In this present work Orodispersible 
tablet of Stavudine was designed with a view to enhance the patient compliance. Oral 
dispersible tablet of Stavudine were prepared by direct compression method after 
incorporating Superdisintegrants sodium Starch glycol ate, Crospovidone, 
Croscarmellose, and kollidon CLM. Twenty formulation having Superdisintegrants at 
different concentration (5, 10, 15, 20%) level were Prepared. The prepared batches of 
tablets were evaluated for Tablet weight variation, content uniformity, hardness and 
friability. Effects of Superdisintegrants on wetting time, dispersion time, and in vitro 
release also have been studied. Tablet containing Kollidon CL M (20%) showed 
excellent in vitro dispersion time and drug release as compared to other formulations. 
After the color and flavor optimization study formulations F18 shows short dispersion 
time (18sec) with maximum drug release in10 min. FTIR & DSC results showed no 
evidence of interaction between the drug and Superdisintegrants.It is concluded that 
Oro dispersible Stavudine tablets could be prepared by direct compression method 
using kollidon CL M superdisintegrants. 
REETA RANI THAKUR. et.al, (19) Oral route is the most convenient route for 
drug administration due to the highest component of compliance mainly the pediatrics 
and geriatrics. It is regarded as the most economical and safest method of drug delivery. 
Formulation of a orally disintegrating dosage form is beneficial for patients suffering 
from motion sickness, repeated emesis, mental disorder and dysphasia because they 
cannot swallow large quantity of water and it is easy to administer. The unique property 
of orally disintegrating dosage form is that they are readily disintegrating and dissolves 
in saliva and avoids the requirement of water which is the major benefit over 
conventional dosage form. Further, drug having the satisfactory absorption from the 
oral mucosa can be formulated in such type of dosage form.. This article includes 
requirement for orally disintegrating tablets, orally disintegrating films, chewing gums, 
oral wafers and buccal patches ,their advantages, disadvantages, challenges in 
formulation ,patented technologies, various technologies developed for formulated 
orally disintegrating dosage form ,super disintegrating agents in the formulation, 
evaluation method and various marketed products. 
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SHARMA ANUP TUKARAMJI, et.al(20),  The primary aim of the present 
work was to formulate and evaluate taste masked dispersible tablets of chloroquine 
phosphate,  an antimalarial drug using ion exchange resins like INDION 294 and 
TULSION 339 as a taste masking agents and superdisintegrating agents like 
crospovidone and sodium starch Glycolate in different concentrations. Characterization 
of drug was done by melting point determination, FTIR spectroscopy and UV 
Spectroscopy. Drug-resin complexes were prepared by Batch method using the resins 
in different ratios. Drug loading study was carried out at different PH. Indion 294 show 
highest release and taste masking ability by determining threshold bitterness 
concentration of the drug. The complexes were characterised by drug content, FTIR 
and DSC studies. Powder blends were prepared and evaluated for various physical 
properties. Dispersible tablets of drug-resin complex (DRC) were prepared by wet 
granulation method using crospovidone and sodium starch Glycolate in different 
concentration as superdisintegrants. Tablets were evaluated for thickness, hardness, 
friability, uniformity of weight, dispersion time, uniformity of dispersion, disintegration 
time, wetting time, wetting volume, content of active ingredient and dissolution studies.  
All the formulations show the evaluated parameters within the acceptable limit for 
dispersible tablets.  
               REKHA RAO, et.al, (21) Amoxicillin though originally introduced in the early 
1970’s for oral use in U.K., has found a gradually regular place as broad spectrum 
antibacterial to treat the infections of various diseases. Amoxicillin has been found to 
be more effective against gram positive than gram negative microorganisms and 
demonstrated greater efficacy to penicillin and penicillin V. Moreover, it has been 
found comparable to other antibiotics, e.g. Ampicillin, Azithromycin, Clarithromycin, 
Cefuroxime And Doxycycline in treatment of various infections/ diseases. In the past 
decade, amoxicillin has been reported to be useful in the management of many 
indications and is used to treat infections of the middle ear (otitis media) , tonsils 
(tonsillitis & tonsillo pharyngitis), throat, larynx (laryngitis) , pharynx (pharyngitis), 
bronchi (bronchitis), lungs (pneumonia), urinary tract (UTI), skin and to treat 
gonorrhoea. Recent studies suggested that it can be used as prophylaxis against 
bacterial endocarditis, in patients with prosthetic joint replacements and in dentistry. 
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The renewed interest of the molecule has prompted a review of the salient features of 
the drug. 
 R. BELMAR-LIBERATO, et.al, (22) In the recent past years, important efforts 
towards the prudent use of antimicrobials have been made in order to optimize 
antibacterial use, and maximize therapeutic effect while minimizing the development of 
resistance. Knowledge on the occurrence of resistance in bacteria could help in 
improving the clinical success of therapeutic decisions. Since the discovery of 
amoxicillin, this drug has been extensively used throughout the world in veterinary 
medicine, alone and also in combination with Clavulanic acid. This paper provides 
information regarding the current situation of resistance to Amoxicillin (And 
Amoxicillin-Clavulanic Acid) in animals in Europe. Most data comes from food-animal 
species, mainly from several national monitoring programmes of antimicrobial 
resistance, and information on companion animals is also available. 
D.INDHUMATHI, et.al, (23) Mouth dissolving tablet offers a solution for 
pediatrics, geriatrics; psychiatric or mentally ill people and those have difficulty in 
swallowing tablets/capsules resulting in improved patient compliance. The aim is to 
formulate fifteen formulations of fast dissolving tablet of Fluoxetine using different 
superdisintegrants (Sodium Starch Glycolate, Croscarmellose, Crospovidone 
Pregelatinized starch) by wet granulation method and the tablets were evaluated for 
various physiochemical properties and found to be within the permissible limit. In vitro 
dissolution studies show the release is in the following order of disintegrants: 
Crospovidone >Pregelatinized starch > Croscarmellose > Sodium Starch Glycolate. 
From the study it has been found and concluded, crospovidone at a concentration of 5% 
w/w (F-XII) shows maximum in-vitro dissolution profile, this is also confirmed by In 
vivo pharmacokinetic studies, and hence it emerged as the overall best formulation 
hence suitable for preparing fast dissolving tablet of Fluoxetine. 
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KAMAL SAROHA. et.al, (24) The desire of improved palatability in orally 
administered products has prompted the development of numerous formulations with 
improved performance and acceptability. Orally Disintegrating tablets (ODTs) have 
received ever-increasing demand during the last few decades, and the field has become 
a rapidly growing area in the pharmaceutical industry. The unique property of mouth 
dissolving tablet is that they are rapidly disintegrating and/or dissolving and release the 
drug as soon as they come in contact with saliva, thus obviate the requirement of water 
during administration. This article reviews the earlier applications and methodologies 
of taste masking and also emphasize on the recent developments and approaches of 
bitterness reduction for orally used pharmaceuticals. Apart from the conventional 
methods of fabrication, this review also provides the detailed concept of some unique 
patents; technologies developed and marketed formulations of Mouth Dissolving 
Tablets (MDTs). 
SUHAS KAKADE. et.al,(25) There is an increasing demand for more patient 
compliant dosage form and a novel method is the development orally disintegrating 
tablets which dissolve or disintegrates instantly on the patient tongue or buccal mucosa. 
It is suited for tablets undergoing high first pass metabolism and is used for improving 
bioavailability with reducing dosing frequency to minimize side effect and make it 
more cost effective. Sertraline is practically slightly soluble in water, its rapidly and 
extensively   absorbed after oral administration, the absolute bioavailability is only 
approximately 44% due to extensive hepatic first pass metabolism. Hence the main 
objective of the study was to formulate orally disintegrating tablets of Sertraline to 
achieve a better dissolution rate and further improving the bioavailability of the drug. 
Orally disintegrating tablets prepared by direct compression and using super 
disintegrants like Crospovidone, Croscarmellose Sodium and Sodium Starch Glycolate 
Designate, designated as three different groups of formulation ( A, B and C) 
respectively were prepared and evaluated for the pre compression parameters such as 
bulk density, compressibility, angle of repose etc. The prepared batches of tablets were 
evaluated for hardness, weight variation, friability, drug content, disintegration time 
and in-vitro dissolution profile and found satisfactory. Among the three groups, group 
(C) containing Crospovidone emerged as the best formulation and showed maximum 
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dissolution rate with 98.49% drug release in 15 min. All three groups of formulations 
released the drug at faster rates than that of marketed conventional tablets of Sertraline. 
M.V.KUMUDHAVALLI, et.al,(26) A rapid, sensitive and specific RP-HPLC 
method involving UV detection was developed  and validated  for determination and 
quantification of Amoxicillin and Potassium Clavulanate. Chromatography was carried 
out on a pre-packed Hypersil C18 (5µm, 250x4.6mm) column using filtered and 
degassed mixture of Phosphate buffer: Methanol (95:05) as mobile phase at a flow rate 
of 1.0ml/min and effluent was monitored at 220nm. The method was validated in terms 
of linearity, precision, accuracy, and specificity, limit of quantification and limit of 
detection. The assay was linear over the concentration range of Amoxicillin and 
Potassium Clavulanate was 25mcg-200mcg/ml and 5mcg to 40mcg/ml respectively. 
Accuracy of the method was determined through recovery studies by adding known 
quantities of standard drug to the pre analyzed test solution and was found to be 
97.70%- 103.00% and 96.80%-102.01% within precision RSD of 0.432 and 0.988 for 
Amoxicillin and Potassium Clavulanate respectively. The system suitability parameters 
such as theoretical plates and tailing factor were found to be 3189.33, 1.225 and 
7852.83, 1.08 respectively for Amoxicillin and Potassium Clavulanate. The method 
does require only 15 minutes as run time for analysis which prove the adoptability of 
the method for the routine quality control of the drug. 
ILMA NUGRAHANI, et.al, (27) The aim of this research was to evaluate solid 
state interaction between Amoxicillin Trihydrate And Potassium Clavulanate. The 
interaction was observed by Differential Scanning Calorimeter (DSC), X-Ray Powder 
Diffractometer (XRPD), Fourier Transforms Infra Red (FTIR) and Scanning Electron 
Microscope (SEM). Mixtures of Amoxicillin Trihydrate And Potassium Clavulanate 
were prepared in molar ratios of 0:10, 1:9, 2:8, 3:7, 4:6; 5:5; 6:4; 7:3; 8:2; 9:1; 10:0 and 
analyzed by DSC to obtain the thermal profile and a phase diagram. From this phase 
diagram, the molar ratio point of interaction was determined. XRPD analysis was 
performed to check the type of physical interaction occurred and FTIR was conducted  
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to predict the chemical mechanism of interaction. Thermo profile obtained by DSC 
analysis of the binary systems showed that endothermic curves of molar fractions of 
1:9—5:5 overlapped at 201°C. On the other hand, the diffractogram obtained from 
Powder X-Ray analysis was very similar with that of Amoxicillin Trihydrate alone. 
FTIR spectrum of binary system in the molar ratio of 5:5 showed the loss of hydrate 
spectra from Amoxicillin Trihydrate. We conclude that the interaction involved strong 
hydrogen bonding between hydrates of Amoxicillin With Potassium Clavulanate which 
produced a co-crystal system like a solid dispersion. 
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                    3. AIM AND OBJECTIVE OF THE STUDY 
The aim of the research work is to formulate and evaluate of Amoxicillin and 
potassium clavulanate dispersible tablet.  
 The oral route is the most frequently used route for drug administration. Oral 
dosage forms are usually for systemic effects resulting from drug absorption through 
the various mucosa of the gastrointestinal tract. The parenteral route of administration 
is an important in mandatory condition; otherwise it is probable that at least 90% of all 
drugs used to produce systemic effects are administered by the oral route. 
 The drugs that are administered orally, solid dosage forms represent the 
preferred class of product. The reasons for this preference are as follows: 
¾ Tablets and capsules represent unit dosage forms in which one unit dose of 
the drug has been accurately placed, whereas in liquid oral dosage forms 
measurements are typically in error when the drug is administered by the 
patient. 
¾ Liquid oral dosage forms are much more expensive to ship and breakage or 
leakage during shipment is a more serious problem than with solid oral 
dosage forms. 
¾ Liquids are less portable and require much more space. 
¾ Drugs are in general less stable in liquid form than in a dry state and 
expiration dates tend to be shorter. 
Compared with other routes, the advantages of the oral solid dosage forms are as 
follows: 
¾ Simplest 
¾ Most compliance 
¾ Safety. 
            The disadvantages include relatively slow onset of action as compared to 
parenterals, difficult to swallow for kids, terminally ill and geriatric patients and 
destruction of certain drugs by the enzymes and the secretion of the GIT. e.g.: Insulin. 
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 The most popular oral dosage forms are tablets, capsules, suspensions, 
solutions, emulsions. The other dosage forms that are administered orally are powders, 
granules, syrups and elixirs. Based on the above advantages, the selected antibiotic 
drug is developed as tablets for oral administration. 
Fast Dissolving Drug Delivery System emerged from the desire to provide 
patient with conventional mean of taking their medication.  
Difficulty in swallowing is a common problem of all age groups, especially 
elderly and paediatrics, because of physiological changes associated with these groups 
of patients other categories that experience problems using conventional oral dosage 
forms includes are the mentally ill, uncooperative and nauseated patients, those with 
conditions of motion sickness, sudden episodes of allergic attack or coughing. 
Sometimes it may be difficult to swallow conventional products due to unavailability of 
water.  
These problems led to the development of novel type of solid oral dosage form 
called “dispersible Tablets”. This tablet disintegrates instantaneously when placed on 
tongue, releasing the drug that dissolves or disperses in the saliva.  
The growing importance of mouth dissolving tablet was underlined recently 
when European Pharmacopoeia adopted the term “Oro dispersible Tablet” as a tablet 
that to be placed in the mouth where it disperses rapidly before swallowing.  
The main criteria for mouth disintegrating (dissolving) tablet is to disintegrate 
or dissolve rapidly in oral cavity with saliva in 15 to 60 seconds, without need of water 
and should have pleasant mouth feel . Mouth dissolving tablets are also known as fast 
dissolving tablet; melt in mouth tablet, rapiment, and porous tablet, dispersible tablet. 
The uses of amoxicillin and clavulanic acid dispersible tablet are used to treat certain 
infections caused by bacteria including infections of the ears, lungs, sinus, skin, and 
urinary tract. 
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OBJECTIVE OF THE STUDY 
 
The aim of the study is to formulate and evaluate of Amoxicillin And Potassium 
Clavulanate dispersible tablets.  
¾ The aim is to formulate formulations of fast dissolving tablet of amoxicillin and 
potassium clavulanate using different disintegrants (Sodium Starch Glycolate, 
Croscarmellose, Crospovidone, Maize starch) by direct compression technique. 
¾ The evaluation of powder blend like Angle of Repose, Bulk Density, Tap 
density, Hausner ratio, Compressibility index is studied. 
¾ Tablets are evaluated for various physiochemical properties.  
¾ The Drug and Excipients Compatibility is studied using FTIR spectral studies. 
¾ The effect of disintegrants on disintegration and dissolution of amoxicillin and 
potassium clavulanate dispersible tablet is also studied extensively.  
¾ Accelerated stability studies are to be carried out for the final Amoxicillin And 
Potassium Clavulanate tablet as per ICH guidelines. 
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                                              4.   PLAN OF WORK 
                           The present work is carried out formulate and evaluate of Amoxicillin & Potassium 
Clavulanate dispersible tablets by using different disintegrants. 
4.1  PREFORMULATION STUDIES 
The drug and excipients compatibility studies is done by using FTIR studies by 
taking FTIR for Amoxicillin, Potassium Clavulanate, and Amoxicillin And Potassium 
Clavulanate and optimized formulation. 
4.2  FORMULATION DEVELOPMENT 
 Prototype formulations is developed using various disintegrants 
4.3.  POWDER BLEND CHARACTERIZATIONS 
• Angle of repose 
• Bulk density 
• Tapped density 
• Carr’s Index 
• Percentage compressibility 
• Hausner ratio 
 
4.4. COMPRESSION PARAMETERS 
4.5.  EVALUATION OF TABLETS 
• Weight variation 
• Hardness of the tablet 
• Friability 
• Thickness 
• Disintegration test 
• Drug content uniformity 
• Fineness of dispersion test. 
 
4.6.  IN VITRO RELEASE STUDIES 
 
4.7.  STABILITY STUDIES 
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5.  DRUG PROFILE 
 
5.1 AMOXICILLIN (28, 29) 
STRUCTURE 
                           
IUPAC 
NAME 
(2S,5R,6R)-6-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-
dimethyl-7-oxo-4-thia-1-azabicyclo 
 
 
DESCRIPTION 
A broad-spectrum semi synthetic antibiotic similar to ampicillin except that its 
resistance to gastric acid permits higher serum levels with oral administration. 
Amoxicillin is commonly prescribed with clauvanic acid (a beta lactamase inhibitor) as 
it is susceptible to beta-lacatamase degradation 
SOLUBILITY 
Slightly soluble in water, very slightly soluble in ethanol (96.0%) practically 
insoluble in fatty oils. It dissolves in dilute acids and dilute solutions of alkali 
hydroxides 
Table No. 1 
CHEMICAL DATA OF AMOXICILLIN 
Formula C16H19N3O5S.3H20 
Molecular mass 419.5g/mol 
 
 
 
 
 
 
43 
 
                                                           Table No .2 
PHARMACOKINETIC DATA OF AMOXICILLIN 
Bioavailability 95 Oral% 
Protein binding 20% 
Metabolism Hepatic Metabolism 
Half-life 61.3 minutes 
Excretion Most of the amoxicillin is excreted unchanged in 
the urine; its excretion can be delayed by 
concurrent administration of probenecid 
 
INDICATION 
For the treatment of infections of the ear, nose, and throat, the genitourinary 
tract, the skin and skin structure, and the lower respiratory tract due to susceptible (only 
b-lactamase-negative) strains of Streptococcus spp. (a- and b-hemolytic strains only), S. 
pneumoniae, Staphylococcus spp., H. influenzae, E. coli, P. mirabilis, or  E. faecalis.  
Also for the treatment of acute, uncomplicated gonorrhea (ano-genital and urethral 
infections) due to N. gonorrhoeae (males and females). 
PHARMACODYNAMICS 
Amoxicillin is a moderate-spectrum antibiotic active against a wide range of 
Gram-positive, and a limited range of Gram-negative organisms. It is usually the drug 
of choice within the class because it is better absorbed, following oral administration, 
than other beta-lactam antibiotics. Amoxicillin is susceptible to degradation by            
β-lactamase-producing bacteria, and so may be given with clavulanic acid to increase 
its susceptability. The incidence of β-lactamase-producing resistant organisms, 
including E. coli, appears to be increasing. Amoxicillin is sometimes combined with 
clavulanic acid, a β-lactamase inhibitor, to increase the spectrum of action against 
Gram-negative organisms, and to overcome bacterial antibiotic resistance mediated 
through β-lactamase production. 
 
MECHANISM OF ACTION 
Amoxicillin binds to penicillin-binding protein 1A (PBP-1A) located inside the 
bacterial cell well. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal 
domain by opening the lactam ring. This inactivation of the enzyme prevents the 
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formation of a cross-link of two linear peptide glycan strands, inhibiting the third and 
last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell 
wall autolytic enzymes such as autolysins; it is possible that amoxicillin interferes with 
an autolysin inhibitor. 
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5.2 POTASSIUM CLAVULANATE (30) 
STRUCTURE 
       
 
           
 
          
IUPAC 
NAME 
(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-
azabicyclo[3.2.0]heptane-2-carboxylic acid 
 
DESCRIPTION 
A white or almost white, crystalline powder  
SOLUBILITY 
Slightly soluble in water, very slightly soluble in ethanol (96.0%) practically 
insoluble in fatty oils. It dissolves in dilute acids and dilute solutions of alkali 
hydroxides 
Table No.3 
CHEMICAL DATA OF POTASSIUM CLAVULANATE 
Formula C8H9NO5  
Molecular mass 199.16 
 
                                                         Table No. 4 
PHARMACOKINETIC DATA POTASSIUM CLAVULANATE 
Bioavailability 75% 
Protein binding Low (22 to 30%) 
Metabolism Hepatic Metabolism 
Half-life 1 Hour 
Excretion Renal (30-40%) 
 
INDICATION 
For use with Amoxicillin, clavulanic acid is suitable for the treatment of 
infections with Staph. aureus and Bacteroides fragilis, or with beta-lactamase 
producing H. influenza and E. coli. 
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PHARMACODYNAMICS 
Clavulanic acid, produced by the fermentation of Streptomyces Clavuligerus, is 
a beta-lactam structurally related to the penicillins. Clavulanic acid is used in 
conjunction with amoxicillin for the treatment of bronchitis and urinary tract, skin, and 
soft tissue infections caused by beta-lactamase producing organisms. 
MECHANISM OF ACTION 
Clavulanic acid competitively and irreversibly inhibits a wide variety of beta-
lactamases, commonly found in microorganisms resistant to penicillins and 
cephalosporins. Binding and irreversibly inhibiting the beta-lactamase results in a 
resaturation of the antimicrobial activity of beta-lactam antibiotics against lactamase-
secreting-resistant bacteria. By inactivating beta-lactamase (the bacterial resistance 
protein), the accompanying penicillin/cephalosporin drugs may be made more potent as 
well. 
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6. EXCIPIENT PROFILE (31, 32, 33) 
 
6.1  AVICEL PH 101 
1. NONPROPRIETARY NAMES 
 
BP            :   Microcrystalline Cellulose 
JP             :   Microcrystalline Cellulose 
Ph Eur      :  Cellulose, Microcrystalline 
USP-NF   :   Microcrystalline Cellulose 
 
2. CHEMICAL NAME AND CAS REGISTRY NUMBER 
      Cellulose [9004-34-6] 
 
3. STRUCTURE FORMULA 
 
4.    EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
       (C 6H 10O 5) n _36 000 
5.    FUNCTIONAL CATEGORY 
    Adsorbent, suspending agent, tablet and capsule diluents, tablet disintegrant. 
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6.  TYPICAL PROPERTIES 
Description 
Microcrystalline cellulose is a purified, partially de polymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. 
It is commercially available in different particle sizes and moisture grades that have 
different properties and applications. 
 
Angle of Repose  :    498 for Ceolus KG; 
                       34.48 For Emcocel 90M. 
Compression Pressure   
Density (True)   :           1.512–1.668 g/cm3 
Melting point Chars at 260–270ºC. 
Moisture content typically less than 5% w/w. 
 
7.  APPLICATION IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes. In addition to its use as a binder/diluent, 
microcrystalline cellulose also has some lubricant and disintegrant properties that make 
it useful in tableting. Microcrystalline cellulose is also used in cosmetics and food 
products. 
 
8.  STABILITY AND STORAGE CONDITIONS 
     Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should  be stored in a well-closed container in a cool, dry place. 
 
9.  INCOMPATIBILITIES 
     Microcrystalline cellulose is incompatible with strong oxidizing agents. 
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6.2 MAIZE STARCH 
 
1. NONPROPRIETARY NAMES 
BP : Maize starch  
  Potato starch 
  Rice Starch 
  Tapioca Starch 
  Wheat Starch 
JP : Corn Starch 
  Potato Starch 
  Rice Starch 
  Wheat Starch 
Ph Eur : Maize Starch 
  Pea Starch 
  Potato Starch 
  Rice Starch 
  Wheat Starch 
USP-NF: Corn Starch 
  Potato Starch 
  Tapioca Starch 
  Wheat Starch 
 
2.   CHEMICAL NAME AND CAS REGISTRY NUMBER 
Starch [9005-25-8] 
 
3.   STRUCTURE FORMULA 
 
 
4.   EMPRICAL FORMULA AND MOLECULAR WEIGHT 
     (C6H10O5) n where n = 300–1000. 
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5.  FUNCTIONAL CATEGORY 
    Tablet and capsule diluent; tablet and capsule disintegrant; tablet binder; 
thickening agent. 
 
6.     TYPICAL PROPERTIES 
Description 
Starch occurs as an odorless and tasteless, fine, white to off-white powder. It 
consists of very small spherical or ovoid granules or grains whose size and shape are 
characteristic for each botanical variety. 
Density (True):  1.478g/cm3 
Moisture Content 
All starches are hygroscopic and absorb atmospheric moisture to reach the 
equilibrium humidity. The approximate equilibrium moisture is characteristic for each 
starch. 
 At 50% relative humidity: 
        12% for corn starch; 
        14% for pea starch, 
        18% for potato starch; 
        14% for rice starch; 
        13% for wheat starch. 
 
 
 
 
 
Excessively dried starches with humidity lower than the equilibrium humidity 
are commercially available. These products should be stored in thermetically sealed 
containers to maintain their low moisture content. 
 
7.  APPLICATION IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
 
Starch is a versatile excipient used primarily in oral solid-dosage formulations 
where it is utilized as a binder, diluents, and disintegrant. As a diluent, starch is used 
for the preparation of standardized triturates of colorants, potent drugs, and herbal 
extracts, facilitating subsequent mixing or blending processes in manufacturing 
operations. Starch is also used in dry-filled capsule formulations for volume adjustment 
of the fill matrix and to improve powder flow, especially when using dried starches. 
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Starch quantities of 3–10% w/w can act as an anti adherent and lubricant in tabletting 
and capsule filling. 
In tablet formulations, freshly prepared starch paste is used at a concentration of 
3–20% w/w (usually 5–10%, depending on the starch type) as a binder for wet 
granulation. The required binder ratio should be determined by optimization studies, 
using parameters such as tablet friability and hardness, disintegration time, and drug 
dissolution rate. 
Starch is one of the most commonly used tablet disintegrants at concentrations 
of 3–25% w/w; a typical concentration is 15%.When using starch, a prior granulation 
step is required in most case to avoid problems with insufficient flow and segregation. 
A starch–lactose compound has been introduced enabling the use of granular starch in 
direct compression, improving the tableting process and the disintegration time of the 
tablets. However, starch that is not pre gelatinized does not compress well and tends to 
increase tablet friability and capping if used in high concentrations Starch, particularly 
the fine powders of rice and wheat starch, is also used in topical preparations for its 
absorbency of liquids. Starch paste is used in ointment formulations, usually in the 
presence of higher ratios of glycerin. Starch has been investigated as an excipient in 
novel drug delivery systems for nasal, and other site-specific delivery systems. The 
retro gradation of starch can be used to modify the surface properties of drug particles. 
Starches are useful carriers for amorphous drug preparations, such as pellets with 
immediate or delayed drug release obtained, for example, by melt extrusion, and they 
can improve the bioavailability of poorly soluble drugs. 
Starch, particularly rice starch, has also been used in the treatment of children’s 
diarrheal diseases. Specific starch varieties with high amylase content (resistant 
starches) are used as insoluble fiber in clinical nutrition, and also for colon-targeting 
applications. Due to their very high gelatinization temperature, these starches are used 
in extrusion/spheronization processes. 
Starches with high amyl pectin content (waxy starches) are used as the starting 
material for the synthesis of hydroxyl ethyl starch, a plasma volume expander. Native 
starches conforming to pharmacopeia specifications are used as the raw materials for 
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the production of starch-based excipients and active pharmaceutical ingredients, 
frequently covered with their own pharmacopeial monographs. 
8.  STABILITY AND STORAGE CONDITIONS 
Dry starch is stable if protected from high humidity. Starch is considered to be 
chemically and microbiologically inert under normal storage conditions. Starch 
solutions or pastes are physically unstable and are readily metabolized by 
microorganisms; they should therefore be freshly prepared when used for wet 
granulation. Starch should be stored in an airtight container in a cool, dry place. 
9.  INCOMPATIBILITIES 
Starch is incompatible with strongly oxidizing substances. Coloured inclusion 
compounds are formed with iodine. 
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6.3.   SODIUM STARCH GLYCOLATE 
1.   NONPROPRIETARY NAMES 
BP               :   Sodium Starch Glycolate 
PhEur         :    Sodium Starch Glycolate 
      USP-NF     :    Sodium Starch Glycolate 
 
2.  CHEMICAL NAME AND CAS REGISTRY NUMBER 
Sodium carboxy methyl starch [9063-38-1] 
 
3.  STRUCTURE FORMULA 
 
 
 
4.  EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
   The USP32–NF27 describes two types of sodium starch glycolate, Type A 
and Type B, and states that sodium starch glycolate is the sodium salt of a carboxy 
methyl ether of starch or of a crosslinked carboxy methyl ether of starch. 
The Ph Eur 6.0 describes three types of material: Type A and TypeB are 
described as the sodium salt of a cross linked partly O carboxy methylated potato 
starch. Type C is described as the sodium salt of a partly O-carboxy methylated starch, 
cross linked by physical dehydration. Types A, B, and C are differentiated by their pH, 
sodium, and sodium chloride content. 
The Ph Eur and USP–NF monographs have been harmonized for Type A and 
Type B variants. 
Sodium starch glycol ate may be characterized by the degree of substitution and 
cross linking. The molecular weight is typically 5 _105–1_106. 
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5.  FUNCTIONAL CATEGORY 
Tablet and capsule disintegrant 
     
6.   TYPICAL PROPERTIES 
Description 
 
Sodium starch glycol ate is a white or almost white free-flowing very 
hygroscopic powder. The Ph Eur 6.0 states that when examined under a microscope it 
is seen to consist of: granules, irregularly shaped, ovoid or pear-shaped, 30–100 mm in 
size, or rounded, 10–35 mm in size; compound granules consisting of 2–4 component 
so occur occasionally; the granules have an eccentric hilum and clearly visible 
concentric striations. Between crossed nicol prisms, the granules show a distinct black 
cross intersecting at the hilum; small crystals are visible at the surface of the granules. 
The granules show considerable swelling in contact with water. 
Density (bulk) 
0.756 g/cm3 for Glycolys; 
0.81 g/cm3 for Primojel; 
0.67 g/cm3 for Tablo. 
Density (tapped) 
0.945 g/cm3 for Glycolys; 
0.98 g/cm3 for Primojel; 
0.83 g/cm3 for Tablo. 
Density (true) 
1.56 g/cm3 for Primojel; 
1.49 g/cm3 for Tablo. 
Melting point does not melt, but chars at approximately 200ºC. 
 
Particle size distribution 100% of particles less than 106 mm in size. Average 
particle size (d50) is 38mm and 42 mm for Primo jel by microscopy and sieving, 
respectively. Solubility Practically insoluble in methylene chloride. It gives a 
translucent suspension in water. 
Specific surface area 
0.24m2/g for Glycolys; 
0.185m2/g for Primojel; 
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0.335m2/g for Tablo. 
 
7.  APPLICATION IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant 
in capsule and tablet formulations. It is commonly used in tablets prepared by either 
direct-compression or wet-granulation processes. The usual concentration employed in 
a formulation is between 2% and 8%, with the optimum concentration about 4%, 
although in many cases 2% is sufficient. Disintegration occurs by rapid uptake of water 
followed by rapid and enormous swelling. 
Although the effectiveness of many disintegrants is affected by the presence of 
hydrophobic excipients such as lubricants, the disintegrant efficiency of sodium starch 
glycolate is unimpaired. Increasing the tablet compression pressure also appears to have 
no effect on disintegration time. 
Sodium starch glycolate has also been investigated for use as a suspending 
vehicle. S 
8.  STABILITY AND STORAGE CONDITIONS 
Tablets prepared with sodium starch glycol ate have good storage properties. 
Sodium starch glycolate is stable although very hygroscopic, and should be stored in a 
well-closed container in order to protect it from wide variations of humidity and 
temperature, which may cause caking. 
The physical properties of sodium starch glycolate remain unchanged for up to 
3 years if it is stored at moderate temperatures and humidity. 
9.  INCOMPATIBILITIES 
Sodium starch glycolate is incompatible with ascorbic acid 
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6.4.  CROS POVIDONE 
1.  NONPROPRIETARY NAMES 
• BP       :  CrosPovidone 
• JP         :  CrosPovidone 
• Ph Eur  :  CrosPovidone 
• USP      :   Povidone 
 
 
2.  CHEMICAL NAME 
     1-Ethenyl-2-pyrrolidinone homo polymer 
 
3.  STRUCTURE FORMULA 
                                  
4.  EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
    (C6H9NO)n                     2500–3 000 000 
 
5.  FUNCTIONAL CATEGORY  
Disintegrant, dissolution enhancer, suspending agent, tablet binder. 
 
6.  TYPICAL PROPERTIES 
Description 
Povidone occurs as a fine, white to creamy-white colored, odourless or almost 
odourless, hygroscopic powder. 
Acidity/alkalinity pH = 3.0–7. 
Density (bulk)   : 0.29–0.39 g/cm3  
Density (tapped): 0.39–0.54 g/cm3  
Density (true)    : 1.180 g/cm3 
Melting point   : 150°C 
Moisture content:  Povidone is very hygroscopic, significant amounts of 
moisture being absorbed at low relative humidities. 
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Solubility    : Freely soluble in acids, chloroform, ethanol (95%), ketones, 
methanol, and water; practically insoluble in ether, hydrocarbons, and mineral oil. In 
water, the concentration of a solution 
Flow ability    : Free flowing 
7.   APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
• CrosPovidone is used in a variety of pharmaceutical formulations; it is primarily 
used in solid dosage forms. 
• CrosPovidone is used as a solubilizer in oral and parenteral formulations, and 
has been shown to enhance dissolution of poorly soluble drugs from solid-
dosage forms. 
8.   STABILITY AND STORAGE CONDITIONS 
CrosPovidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. The powder is hygroscopic; it should be stored in an 
airtight container in a cool, dry place. 
9.   INCOMPATIBILITIES 
Crospovidone is compatible in solution with a wide range of inorganic salts, 
natural and synthetic resins, and other chemicals. 
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6.5.   CROSCARMELLOSE SODIUM 
1.  NONPROPRIETARY NAMES 
BP          :  Croscarmellose Sodium 
JP           :  Croscarmellose Sodium 
Ph Eur     :  Croscarmellose Sodium 
USP-NF  :  Croscarmellose Sodium 
 
2.  CHEMICAL NAME 
Cellulose, carboxy methyl ether, sodium salt 
3.  STRUCTURE FORMULA 
                    
 
4.  EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
Croscarmellose sodium is a cross linked polymer of carboxy methyl cellulose 
sodium. 
5.  FUNCTIONAL CATEGORY 
Tablet and capsule disintegrant.  
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6.  TYPICAL PROPERTIES 
Description  
Croscarmellose sodium occurs as an odorless, white or grayish white powder. 
Density (tapped): 0.819 g/cm3 for Ac-Di-Sol 
Density (true): 1.543 g/cm3 for Ac-Di-Sol 
 
to 4–8 times its original volume on contact with water. Practically insoluble in 
acetone, ethanol and toluene. 
Specific surface area:  0.81–0.83m2/g 
7.  APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets, and granules.  In tablet formulations, croscarmellose 
sodium may be used both direct-compression and wet-granulation processes. 
 
8.  STABILITY AND STORAGE CONDITION 
Croscarmellose sodium is a stable though hygroscopic material. A model tablet 
formulation prepared by direct compression, with croscarmellose sodium as a 
disintegrant. Croscarmellose sodium should be stored in a well-closed container in a 
cool, dry place. 
9.  INCOMPATIBILITIES 
Croscarmellose sodium is not compatible with strong acids or with soluble salts 
of iron and some other metals such as Aluminum, Mercury, And Zinc. 
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6.6 AEROSIL 
1.  NONPROPRIETARY NAMES 
BP  :  Colloidal Anhydrous Silica 
JP  :  Light Anhydrous Silicic Acid 
PhEur  :  Silica, Colloidal Anhydrous 
USP-NF :  Colloidal Silicon Dioxide 
 
2.  CHEMICAL NAME 
Silica [7631-86-9] 
2. STRUCTURE FORMULA 
 
4.  EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
SiO2 60.08 
5.  FUNCTIONAL CATEGORY 
Adsorbent; anti caking agent; emulsion stabilizer; glidant; suspending agent; 
tablet disintegrant; thermal stabilizer; 
 Viscosity-increasing agent. 
6.  TYPICAL PROPERTIES 
Description 
Colloidal silicon dioxide is sub microscopic fumed silica with a particle size of 
about 15 nm. It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous 
powder. 
Density (Bulk)           : 0.029-0.042 
Melting point   : 1600ºC 
Particle size distribution  
Primary particle size is 7–16 nm. Aerosil forms loose agglomerates of 10–200 
mm.  
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Refractive index: 1.46 
Solubility 
Practically insoluble in organic solvents, water, and acids, except hydrofluoric 
acid; soluble in hot solutions of alkali hydroxide. Forms a colloidal dispersion with 
water. For Aerosil, solubility in water is 150 mg/L at 258C (pH 7). 
 
Specific gravity: 2.2 
 
7.  APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food 
products Its small particle size and large specific surface area give it desirable flow 
characteristics that are exploited to improve the flow properties of dry powders in a 
number of processes such as tableting and capsule filling. Colloidal silicon dioxide is 
also used to stabilize emulsions and as a thixotropic thickening and suspending agent in 
gels and semisolid preparations. With other ingredients of similar refractive index, 
transparent gels may be formed. The degree of viscosity increase depends on the 
polarity of the liquid (polar liquids generally require a greater concentration of colloidal 
silicon dioxide than nonpolar liquids). Viscosity is largely independent of temperature. 
However, changes to the pH of a system may affect the viscosity. In aerosols, other 
than those for inhalation, colloidal silicon dioxide is used to promote particulate 
suspension, eliminate hard settling, and minimize the clogging of spray nozzles. 
Colloidal N silicon dioxide is also used as a tablet disintegrant and as an dispersing 
agent for liquids in powders. Colloidal silicon dioxide is frequently added to 
suppository formulations containing lipophilic excipients to increase viscosity, prevent 
sedimentation during molding, and decrease the release rate. Colloidal silicon dioxide 
is also used as an adsorbent during the preparation of wax microspheres; as a 
thickening agent for topical preparations; and has been used to aid the freeze-drying of 
nano capsules and Nanosphere suspensions. 
 
8.  STABILITY AND STORAGE CONDITION 
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water 
without liquefying. When used in aqueous systems at a Ph 0–7.5, colloidal silicon 
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dioxide is effective in increasing the viscosity of a system. However, at a pH greater 
than 7.5 the viscosity increasing properties of colloidal silicon dioxide are reduced; and 
at a pH greater than 10.7 this ability is lost entirely since the silicon dioxide dissolves to 
form silicates.(14) Colloidal silicon dioxide powder should be stored in a well-closed 
container. 
 
9.  INCOMPATIBILITIES 
Incompatible with diethyl stilbestrol preparations. 
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6.7   ASPARTAME 
1.  NONPROPRIETARY NAMES 
BP  :   Aspartame 
PhEur  :  Aspartame 
USP-NF :  Aspartame 
 
2.  CHEMICAL NAME 
N-L-a-Aspartyl-L-phenylalanine 1-methyl ester [22839-47-0] 
3. STRUCTURE FORMULA 
    
4.  EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
        C14 H18N2O5 294.30 
5.  FUNCTIONAL CATEGORY 
     Sweetening agent 
6.  TYPICAL PROPERTIES 
    Description 
    Aspartame occurs as an off white, almost odorless crystalline powder with an 
intensely sweet taste.  
 
ACIDITY/ALKALINITY 
 
pH = 4.5–6.0 (0.8% w/v aqueous solution) 
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BRITTLE FRACTURE INDEX 1.05 
BONDING INDEX 
 
0.8_102 (worst case) 
2.3_102 (best case) 
 
FLOWABILITY 
44% (Carr compressibility index) 
 
DENSITY (BULK) 
 
0.5–0.7 g/cm3 for granular grade; 
0.2–0.4 g/cm3 for powder grade; 
0.17 g/cm3 (Spectrum Quality Products). 
 
DENSITY (TAPPED)  
0.29 g/cm3 (Spectrum Quality Products) 
DENSITY (TRUE) 1.347 g/cm3 
 
Effective angle of internal friction 43.08 
 
Melting point 246–247ºC 
 
SOLUBILITY 
 
 Slightly soluble in ethanol (95%); sparingly soluble in water. At 208C the 
solubility is 1% w/v at the iso electric point (pH 5.2). Solubility increases at higher 
temperature and at more acidic pH, e.g., at pH 2 and 208C solubility is 10% w/v. 
 
SPECIFIC ROTATION  
22 =_2.38 in 1N HCl 
 
 
7. APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
Aspartame is used as an intense sweetening agent in beverage products, food 
products, and table-top sweeteners, and in pharmaceutical preparations including 
tablets powder mixes, and vitamin preparations. It enhances flavor systems and can be 
used to mask some unpleasant taste characteristics; the approximate sweetening power 
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is 180–200 times that of sucrose. Unlike some other intense sweeteners, aspartame is 
metabolized in the body and consequently has some nutritive value: 1 g provides 
approximately 17 kJ (4 kcal). However, in practice, the small quantity of aspartame 
consumed provides a minimal nutritive effect. 
 
8.  INCOMPATIBILITIES 
Differential scanning calorimetry experiments with some directly compressible 
tablet excipients suggests that aspartame is incompatible with dibasic calcium 
phosphate and also with the lubricant magnesium stearate.  Reactions between 
aspartame and sugar alcohols are also known 
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6.8 STRAWBERRY FLAVOUR 
 
1. NONPROPERIATARY NAMES 
BP  : Strawberry flavor 
PhEur  : Strawberry flavor 
USP-NF : Strawberry flavour 
 
2.  CHEMICAL NAME 
(E)-2-pentenal butyric acid 
3.  STRUCTURAL FORMULA 
 
 
4.  FUNCTIONAL CATEGORY 
    Flavouring agent. 
 
5.  APPLICATION IN PHARMACEUTICAL FIELD 
It is used in various pharmaceutical products. 
     Oral 
Cough drops /Lozenges 
          Cough syrups 
Mouth sprays 
           Mouth wash 
           Toothpaste 
External 
         Lip balms 
         Ointments 
         Salves 
         Sprays 
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6.9   MAGNESIUM STERATE 
 
MAGNESIUM STEARATE 
 
1.  NONPROPRIETARY NAMES: 
BP  :    Magnesium Stearate 
JP  :    Magnesium Stearate 
PhEur  :    Magnesium Stearate 
USP-NF :    Magnesium Stearate 
 
2.  CHEMICAL NAME 
Octadecanoic acid 
 
3.  STRUCTURE FORMULA 
[CH3(CH2)16COO]2Mg 
 
4.  EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
     C36H70MgO4                           591.24 
 
5.  FUNCTIONAL CATEGORY 
Tablet and capsule  
 
6.  DESCRIPTION 
Magnesium sterate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic 
taste. The powder is greasy to the touch and readily adheres to the skin. 
TYPICAL PROPERTIES 
           Crystalline forms High-purity magnesium stearate has been isolated as a 
trihydrate, a dihydrate, and an anhydrate. 
Density (bulk)     :  0.159 g/cm3 
Density (tapped)  :   0.286 g/cm3 
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Density (true)      :   1.092 g/cm3 
Flash point          :  250°C 
Flow ability         :  Poorly flowing, cohesive powder. 
Melting range      :  117–150°C 
Solubility   : Practically insoluble in ethanol, ethanol (95%), ether and water; 
slightly soluble in warm benzene and warm ethanol (95%). 
Specific surface area :  1.6–14.8m2/g 
 
7.  APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
• Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations.  
• It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. 
•  It is also used in barrier creams. 
 
8.  STABILITY AND STORAGE CONDITIONS 
Magnesium stearate is stable and should be stored in a well-closed container in 
a cool, dry place. 
 
9.  INCOMPATIBILITIES 
Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin, 
some vitamins, and most alkaloidal salts. 
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6.10  YELLOW OXIDE OF IRON  
1.  NONPROPRIETARY NAMES: Iron oxide yellow monohydrate: E172; 
hydrated ferric oxide; iron (III) oxide monohydrate, yellow; pigment yellow 42; yellow 
ferric oxide. Iron (III) oxide hydrated: Bayferrox920Z; CI 77492; ferric hydroxide; 
ferric hydroxide oxide; ferric hydrate; ferric oxide hydrated; Ferroxide 510P; iron 
hydrate; iron hydroxide; iron hydroxide oxide; Mapico Yellow EC; Sicovit Y10; 
yellow ochre; yellow iron oxide 
2.  CHEMICAL NAME: Iron oxide yellow [51274-00-1] (monohydrate); [20344-
49-4] (hydrate) Iron oxide yellow [51274-00-1] (monohydrate) [20344-49-4] (hydrate) 
3  STRUCTURE FORMULA Iron oxides are defined as inorganic compounds 
consisting of anyone of or combinations of synthetically prepared iron oxides, 
including the hydrated forms 
4.  EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
a)  Fe 3O 4 231.54 
b)  Fe 2O3 159.70 
c)  Fe 2O3_H 2O 177.70 (monohydrate); FeHO2 88.85 
(hydrate) 
5.  FUNCTIONAL CATEGORY 
Colorant 
6.  TYPICAL PROPERTIES 
4.1 g/cm3 for iron oxide yellow (Fe 2O 3_H 2O). 
Solubility Soluble in mineral acids; insoluble in water. 
7. APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
Iron oxides are widely used in cosmetics, foods, and pharmaceutical 
applications as colorants and UV absorbers. As inorganic colorants they are becoming 
of increasing importance as a result of the limitations affecting some synthetic organic 
dyestuffs.  However, iron oxides also have restrictions in some countries on the 
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quantities that may be consumed, and technically their use is restricted because of their 
limited color range and their abrasiveness. 
 
8.  STABILITY AND STORAGE CONDITIONS 
      Iron oxides should be stored in well-closed containers in a cool, dry place. 
 
9.  INCOMPATIBILITIES 
Iron oxides have been reported to make hard gelatin capsules brittle at higher 
temperatures when the residual moisture is 11–12%. This factor affects the use of iron 
oxides for coloring hard gelatin capsules, and will limit the amount that can be 
incorporated into the gelatin material. 
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7.  MATERIALS AND METHODS 
7.1 LIST OF INSTRUMENTS AND MANUFACTURER 
 
Table No. 5. LIST OF INSTRUMENTS AND MANUFACTURER 
S.NO EQUIPMENTS MANUFACTURER 
1 Tablet compression machine-27 
station(single Rotary) 
CIP Machinery 
2 Die Punch CIP Machinery 
3 Planetary Mixer Kenwood 
4 Hot air oven Lab India 
5 Dissolution apparatus(usp) Electro lab 
6 Electromagnetic sieve shaker(ESM-8) Electro lab 
7 Tablet Hardness tester(8M) Dr.Schleuniger, pharmaton 
USA 
8 PH meter Lab India 
9 Reverse phase High Pressure Liquid 
chromatography (HPLC) 
Shimadzu 
10 Electronic Weighing Balance Essec  Teraoka Lid(Japan) 
11 Digital high precision balance(single 
pan) 
Mettler-
Toledo(Switzerland) 
12 Disintegration tester Electro Lab 
13 Roche Friabilator USP Electro Lab 
14 Mechanical stirrer Remi Motors, Bombay 
15 Tabbed density tester Electro Lab 
16 Bulk density apparatus Electro Lab 
17 Stability chambers Thermo lab,Mumbai 
18 Sieves (A.S.T.M) Rajdhani 
19 Digital Vernier Calipers CD-6 inch 
CSX 
Mitutoyo Corp, Japan 
20 Humidity Chamber HTC 3003 Thermo lab 
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7.2 DRUG EXCIPIENTS AND THE MANUFACTURER 
             
Table No. 6. DRUG EXCIPIENTS AND THE MANUFACTURER 
S.No Materials Name 
 
COMPANY NAME 
1. Amoxicillin trihydrate (powder) 
BP 
DSM Anti Infectives India Ltd. India 
2. Colloidal silicon dioxide 
(Aerosil) USP/BP 
Degussa, Germany 
3. Maize starch USP/BP Maize Products, Ahemedabad, India 
4. Potassium Clavulanate + Avicel 
blend (1: 1) BP 
Fermic, S.a.de c.v, Mexico D.F / LEK 
Pharmaceuticals, Germany 
5. Microcrystalline cellulose 
(Avicel pH 101) USP/BP 
FMC Biopolymer, Ireland. 
6. Powdarome Strawberry 
Premium flavor IH  
Firmenich.  
7 Yellow oxide of irons Roha Dyes & Chemicals. 
8 Magnesium stearate USP/BP Nitika Chemicals, Nagpur 
 9 Sodium starch Glycolate Signet pharma agencies, 
Mumbai. 
10 Crospovidone ISP Technologies, USA 
11 Croscarmellose Sodium Signet Pharma Agencies Mumbai. 
12 Aspartame Firmenich 
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8.  EXPERIMENTAL WORK 
 
CALIBRATION CURVE OF AMOXICILLIN TRIHYDRATE 
100 mg of amoxicillin trihydrate was accurately weighed and dissolved in 25 ml of 
methanol in 100 ml volumetric flask and volume was made up to the mark using 
methanol, to make (1000 µg/ml) standard stock solution. Then 2 ml stock solution was 
taken in another 100 ml volumetric flask and further diluted in 100 ml of methanol to 
make  (20 µg/ml) standard stock solution, then  final concentration were prepared with 
water. The absorbance of standard solution was determined using UV/VIS 
spectrophotometer at 220nm (26) 
CALIBRATION CURVE OF DILUTED POTASSIUM CLAVULANATE: 
Accurately weighed 100mg Diluted Potassium Clavulanate was transferred into 100ml 
volumetric flask and dissolved in small quantity of methanol and the volume was made 
up with water to give a stock solution of concentration of 1mg?ml. further dilutions 
were made in the range of 2-10mcg/ml with water and absorbance was measured at 220 
nm(26) 
PREFORMULATION STUDIES  
IR SPECTROSCOPIC ANALYSIS(27) 
The IR absorption spectra of the pure drug and with different excipients were 
taken in the range of 4000-400 cm-1 using KBR disc method. Triturate 1-2 mg of the 
substance to be examined with 300-400 mg, specified quantity; of finely powered and 
dried Potassium bromide .These quantities are usually sufficient to give a disc of 10-
15mm diameter and spectrum of suitable intensity by a hydraulic press. The Infrared 
spectrum of Amoxicillin and Potassium Clavulanate was recorded by using FT-IR 
spectroscopy and observed for characteristic peaks of drug 
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METHOD OF PREPARATION 
FORMULATION COMPOSITIONS 
In the present research work, a dispersible tablet of Amoxicillin and Potassium 
Clavulanate was formulated using direct compression method . Wet granulation method 
was not used because this formulation is highly sensitive to moisture and temperature 
conditions(11). Therefore Direct compression method was used for the manufacture of 
Amoxicillin and Potassium Clavulanate dispersible tablets. 
Sixteen formulations were prepared by direct compression method using 
different disintegrants in various ratios of from F1 to F4 using maize starch as  
disintegrant in the ratios of 5, 10, 12.5 and 15,  and F5 to F8 using CCS as disintegrant 
in the ratios of 5, 10, 12.5 and 15,  and F9 to F12 using Crospovidone as disintegrant in 
the ratios of 5, 10, 12.5 and 15, and F13 to F16  using  sodium starch glycolate as 
disintegrant in the ratios of 5, 10, 12.5 and 15. All the formulation and composition was 
shown in Table No: 7. 
The Commonly used sweetening agents are Aspartame, Sugar derivative, 
Dextrose, Fructose, Mannitol, Sorbitol, Maltose etc. In this present study Aspartame is 
used as sweetening agent. 
          The Commonly used Flavouring agents are Vanila, Citrus oil, Fruit essence, 
Eucalyptus oil, clove oil, Peppermint oil, strawberry flavor. In this present study 
Strawberry flavor is used as a flavouring agent. 
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Table No.7 
Composition of formulations (F1 – F16) 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15
Amoxicillin 234.3 234.3 234.3 234.3 234.3 234.3 234.3 234.3 234.3 234.3 234.3 234.3 234.3 234.3 234.
Potassium 
Clavulanate 
75.70 75.70 75.70 75.70 75.70 75.70 75.70 75.70 75.70 75.70 75.70 75.70 75.70 75.70 75.7
MCC AVICEL 
PH 101 
149 144 141.5 139 149 144 141.5 139 149 144 141.5 139 149 144 141.
Maize starch 5 10 12.5 15 - - - - - - - - - - -
Croscarmellose 
sodium 
- - - - 5 10 12.5 15 - - - - - - -
Crospovidone - - - - - - - - 5 10 12.5 15 - - -
SSG - - - - - - - - - - - - 5 10 12.5
Aerosil 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Aspartame 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15
Strawberry 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
Magnesium 
stearate 
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Yellow oxide of 
Iron 
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Total Weight 500  500 500 500 500 500 500 500 500 500 500 500 500 500 500
 
F1 –F4: Maize starch, F5-F8: Croscarmellose sodium, F9 – F12 : Crospovidone F13-F16: Sodium starch glycolate (SSG)
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EVALUATION OF BLEND  
The evaluation of blend was done by the following parameters 
a)  ANGLE OF REPOSE (34,35 ,36,) 
 
The frictional force in a loose powder can be measured by the angle of repose. 
Angle of Repose is the maximum angle between the surface of a pile of powder and 
horizontal plane. It is usually determined by fixed funnel method and is the measure of 
the flow ability of powder/granules. 
A funnel with 10 mm inner diameter of stem was fixed at a height of 2 cm over 
the platform. About 10 gm of sample was slowly passed along the wall of the funnel till 
the tip of the pile formed and touches the steam of the funnel. A rough circle was drawn 
around the pile base and the radius of the powder cone was measured48. 
Angle of repose was calculated from the average radius using the following 
Formula. 
                   θ = Tan-1 (h/r)          Where, 
                       θ = Angle of repose 
                       h = Height of the pile 
                       r = Average radius of the powder cone 
 
Table No 8 
Limitation of Angle of repose 
                      Angle of repose Type of flow 
< 25 Excellent 
25 – 30 Good 
30 – 40 Passable 
> 40 Very Poor 
 
Higher the angle of repose the rougher and more irregular is the surface of the particles. 
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b)  BULK DENSITY (34, 35, 36) 
Bulk density of a compound varies substantially with the method of 
crystallization, milling or formulation. Usually, bulk density is of great importance when 
none considers the size of a high-dose drug product or homogeneity of a low-dose 
formulation. Apparent bulk density (g/ml) of all types of drug were determined by 
pouring preserved (40-mesh) gently 25 gm of sample through a glass funnel into a 100 ml 
graduated cylinder. Bulk density was calculated. 
                Weight of sample (gm) 
Bulk density (g/ml) =    -------------------------------------------------------- 
                                              Volume occupied by the sample (ml) 
 
The Bulk Characterization is done in Electrolab-Tap Density Tester by method 
USP-I. 
c)  TAPPED DENSITY (34, 35, 36) 
Tapped densities of all types of granules were determined by pouring gently 25 
gm of sample through a glass funnel into a 100 ml graduated cylinder. The cylinder was 
tapped from height of 2 inches until a constant volume was obtained.  
In USP TAP DENSITY TESTER, tap density is measured in 500 taps, 750 taps & 
1250 taps with drop/time-249 .Volume occupied by the sample after tapping were 
recorded and tapped density was calculated. 
             Weight of sample (gm) 
Tap density (g/ml) = 
               Volume occupied by the sample (ml) 
 
Experimentally, the true density of a powder is determined by suspending drug 
particles in solvents of various densities and in which the compound is insoluble. Wetting 
and penetration may be enhanced by addition of some quantities of surfactant to the 
solvent mixture. After centrifuging the suspending molecule the exact tap density is 
determined 
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d)  PERCENTAGE COMPRESSIBILITY (34, 35, 36,)  
Compressibility is the ability of powder to decrease in volume under pressure 
.Compressibility is a measure that is obtained from density determinations. It is also one 
of the simple methods to evaluate flow property of powder by comparing the bulk density 
and tapped density. A useful empirical guide is given by the Carr’s compressibility or 
compressibility index. Compressibility measures gives idea about flow property of the 
granules as per Carr’s index which is as follow 
Table No. 9 
Limitation of Percentage compressibility index 
          Compressibility Flow description 
5 – 15 Excellent 
12 – 16 Good 
18 – 21 Fair 
23 – 35 Poor 
35 – 38 Very poor 
> 40 Extremely poor 
 
e)  HAUSNER RATIO (, 34, 35, 36) 
 
It provides an indication of the degree of densification which could result from 
vibration of the feed hopper. 
Bulk density 
Hausner ratio = Tapped density 
Lower Hausner ratio − better flowability 
Higher Hausner ratio − poor flow ability                                                                                                     
Table No.10 
Limitation of Hausner’s Ratio 
 
                         Hausner’s ratio            Type of flow 
<1.25 Good flow 
1.25 – 1.5 Moderate 
>1.5 Poor flow 
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MANUFACTURING PROCESS OF DISPERSIBLE TABLET 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
 
 
 
 
 
 
 
 
 
 
Figure No. 4 Flowchart for manufacturing of Dispersible Tablets 
Amoxicillin trihydrate was shifted 
through ≠20 mesh 
Potassium Clavulanate passed through 
≠40 mesh 
 The disintegrants were passed through ≠ 
40 
Both blends were mixed 
 
Mixed blend was sifted through sieve no 
≠24 mesh 
Remaining amount of aspartame, flavor 
and talc were shifted through ≠40mesh 
and color shifted through ≠60mesh 
Magnesium stearate was sifted through 
≠60 mesh and mixed with the powder 
blend  
Blend was compressed to prepare tablets 
12.8mm, 
circular flat 
punch, 
27 station 
compressed 
machine, 
Mfg:CIP 
machinery 
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MANUFACTURING PROCEDURE 
• Amoxicillin trihydrate was shifted (Electrolab) through≠ 20 mesh 
• Potassium Clavulanate, disintegrant all were passed through ≠40 mesh. Both 
blends (Kenwood planetary mixer) were mixed. 
• Mixed blend was sifted through sieve no ≠24 mesh. 
• Remaining amount of aspartame, flavor and talc were shifted through ≠40mesh 
and colour shifted through ≠60 mesh. 
• Magnesium stearate was sifted through ≠ 60mesh and mixed with the  powder 
blend  
• Blend was compressed to prepare tablets.  
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EVALUATION OF TABLETS (37) 
IPQC TESTS: 
 
After Compression all the tablets should be checked for the physical appearance 
and   removal of any obvious defective tablets.  
All the tablets should be inspected only on the tablet inspection belt attached with 
metal detector.  
Record the weight of good tablets and rejection for each batch.  
a)   SHAPE OF TABLETS 
Randomly picked tablets from each formulation were examined for the shape of 
the tablets.  
b)   WEIGHT VARIATION  
The test ensures that all the tablets in each batch are of same potency, within 
reasonable limits. Each tablet in the batch should be uniform in weight and weight 
variation if any, should be generally within ± 10% for tablets weighing 130 mg or less, ± 
7.5% for tablets weighing more than 130 mg and up to 324 mg and ± 5% for tablets 
weighing 325 mg or more. According to the official test, 20 tablets were weighed 
individually and collectively. Average weight per tablet was calculated from the 
collective weight. Then the weights of the individual tablets were compared with the 
average weight to determine weight variation. 
c)   HARDNESS TEST  
Tablets require a certain amount of strength, or resistance to friability, to 
withstand the mechanical shocks of handling in manufacture, packaging, and shipping. 
The strength of the tablet was determined by Dr Schleuniger pharmaton apparatus. The 
force of fracture was recorded. 
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d)     FRIABILITY  
Friability test was performed to assess the effect of friction and shock which may 
often cause tablets to chip, cap or break. It generally reflects poor cohesion of tablet 
ingredients. Weighed tablets sample was placed in the chamber and the friabilator was 
operated for 100 revolutions at 25 RPM and the tablets were weighed again. Compressed 
tablets should not lose more than 1% of their weight. 
e)    TABLET THICKNESS  
Variation in the tablet thickness may cause problems in counting and packaging in 
addition to weight variation beyond the permissible limits. Tablet thickness should be 
controlled within a ± 3% of a standard value. Tablet thickness was measured by Vernier 
calipers. 
DISINTEGRATION TEST 
The disintegration time was determined by using USP Tablet disintegration test 
apparatus using 900 ml of distilled water without disk. Time taken by tablets (Sec) for 
complete disintegration of the tablets until no mass remaining in apparatus was measured. 
UNIFORMITY OF DISPERSION TEST (38) 
The fineness of dispersion test was done by place 2 tablets in 100 ml of water and 
stir until completely dispersed. A smooth dispersion is produced, which passes through a 
sieve no. #25. 
WETTING TIME 
The wetting time and capillarity of oral dispersible tablets were measured by a 
conventional method. Tablet was placed in a petri dish containing 10 ml water at room 
temperature and the times for complete wetting of tablets were recorded. 
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DRUG CONTENT UNIFORMITY 
The drug content was done by chromatographic method. 
 
CHROMATOGRAPHIC CONDITIONS 
 
Column                     :  C18, 250mmX4.0m, 5µm. 
Detector                     :  UV detector at 220 nm 
Manufacturer Name    :  schimadzu 
Flow rate                   :  2.0 ml/min 
Temperature              :  Ambient 
Buffer preparation       :  Dissolve 7.8 g of Sodium di-hydrogen orthophosphate in 
1000 ml of water with a ortho-phosporic acid to a Ph OF 
4.4 
MOBILE PHASE 
 
A mixture of Buffer &Methanol (950:50), filter and degas. Standard solution: 
weigh accurately 50 mg of Amoxicillin Trihydrate WS. And 46.0mg Diluted Potassium 
Clavulanate WS. In 100 ml volumetric flask. Add 60 ml water, sonicate to dissolve, and 
make up volume with water. 
 
SAMPLE PREPARATION  
 
Weigh and powdered 20 tablets, transfer powder containing 250mg Amoxicillin 
in 500 ml volumetric flask. Add 400ml of water and sonicate to dissolve. Make up the 
volume up to the mark with water. Filter the sample solution through 0.45 µm membrane 
filter paper. 
 
PROCEDURE 
 
Separately inject 20µl of the standard solution in replicate and calculate RSD of 
standard area (RSD NMT 2.0%), tailing factor NMT 2.0 and the column efficiency is 
NLT 1500 theoretical plates, Inject Test solution into the chromatogram and record the 
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chromatograph and measure the response for the major peaks and calculate the result by 
comparison 
CALCULATION 
Amoxicillin (Release in %) 
 =  Spl area    Std wt     5      900      Std purity          100 
  x    x       x        x        x  
Avg. std area       100                25         1              100             Label claim 
 
POTASSIUM CLAVULANATE (RELEASE IN %) 
=  Spl area            Std wt            5       900       Std purity            100 
         x              x        x          x              x  
Avg. std area          100                25            1             100             Label claim 
 
IN VITRO DRUG RELEASE STUDIES: 
 
The in vitro dissolution of amoxicillin and potassium clavulanate dispersible 
tablets prepared by direct compression method using Dissolution test apparatus TDT- 
06T (Electro lab, Mumbai, India) at the USP type II apparatus at 75rpm. The dissolution 
studies were conducted in 900 ml of water as a dissolution media at 37°C + 0.5 ºC. 
Optimized batches Amoxicillin and Potassium Clavulanate dispersible tablet from F1-
F16 were suspended in 900 ml of water was withdrawn at 0, 5, 10, 15, 30, 60, 180, 
300,600,900 sec with a pipette and filter through 0.45µm what man filter and then 
analyzed Amoxicillin and Potassium Clavulanate dispersible tablet content was 
determined in triplicate by (UV/Vis Spectrophotometer, Shimadzu - 1800) 
spectrophotometrically at_max 220 nm. Fresh medium (5 ml) which was pre warmed at 
37°C and was replaced immediately into the dissolution medium after each sampling 
maintain its constant volume throughout the test.  
 
AMOXICILLIN (RELEASE IN %) 
 Spl area             Std wt          5             900         Std purity            100 
   x  x     x         x          x  
Avg. std area          100             25               1             100                 Label claim 
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POTASSIUM CLAVULANATE (RELEASE IN %) 
 Spl area             Std wt          5             900         Std purity            100 
   x  x     x         x          x  
Avg. std area          100             25               1             100                 Label claim 
 
STABILITY (39, 40, 41) 
 
The term “stability,” with respect to a drug dosage form, refers to the chemical 
and physical integrity of the dosage unit and, when appropriate, the ability of the dosage 
unit to maintain protection against microbiological contamination. The shelf life of the 
dosage form is the time lapse from initial preparation to the specified expiration date. The 
monograph specifications of identity, strength, quality, and purity apply throughout the 
shelf life of the product. 
The stability parameters of a drug dosage form can be influenced by 
environmental conditions of storage (temperature, light, air, and humidity), as well as the 
package components. Pharmacopeia articles should include required storage conditions 
on their labelling. These are the conditions under which the expiration date shall apply. 
The storage requirements specified in the labelling for the article must be observed 
throughout the distribution of the article (i.e., beyond the time it leaves the manufacturer 
up to and including its handling by the dispenser or seller of the article to the consumer). 
Although labeling for the consumer should indicate proper storage conditions, it is 
recognized that control beyond the dispenser or seller is difficult. The beyond-use date 
shall be placed on the container label. 
STABILITY PROTOCOLS  
Stability of manufactured dosage forms must be demonstrated by the 
manufacturer, using methods adequate for the purpose. Monograph assays may be used 
for stability testing if they are stability-indicating (i.e., if they accurately differentiate 
between the intact drug molecules and their degradation products). Stability 
considerations should include not only the specific compendial requirements, but also 
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changes in physical appearance of the product that would warn users that the products 
continued integrity is questionable. 
Stability studies on active substances and packaged dosage forms are conducted 
by means of “real-time,” long-term tests at specific temperatures and relative humidities 
representing storage conditions experienced in the distribution chain of the climatic 
zone(s) of the country or region of the world concerned. Labeling of the packaged active 
substance or dosage form should reflect the effects of temperature, relative humidity, air, 
and light on its stability. Label temperature storage warnings will both reflect the results 
of the real-time storage tests and allow for expected seasonal excursions of temperature. 
Table No 11: The stability Protocol was given in the following table 
Study Storage condition Minimum time period 
covered by data at 
submission 
Long term 25±2ºC and 60±5% RH 
              Or 
30±2ºC and 65±5% RH     
         12 months 
Intermediate 30±2ºC and 65±5% RH           6 months 
Accelerated 40±2ºC and 75±5% RH          6  months 
 
 PROCEDURE 
 
The stability studies were conducted by storing the tablet in a stability chamber at 
25±2ºC/60±5% RH and 40±2ºC/75±5% RH. The tablets are wrapped in ALU-ALU pack 
and its stored for one month. After one month, tablets were analyzed for its physical 
properties and dissolution profile. 
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                                       9. RESULTS AND DISCUSSION 
 
1. PRE-FORMULATION STUDIES 
CALIBRATION CURVE  
FOR AMOXICILLIN TRIHYDRATE: 
Calibration curve of Amoxicillin Trihydrate was prepared in water at determined 
wavelength 220nm. The calibration curve was linear between 20 to 100 µg/ml 
concentration ranges. The r2 and slope were found to be 0.993 and 0.005 shown in figure 
no. 5 and table no. 12. 
FOR POTASSIUM CLAVULANATE: 
Calibration curve of Potassium Clavulanate was developed in water at above 
determined wavelength 220nm. The calibration curve was linear between 2 to 10 µg/ml 
concentration ranges. The r2 and slope were found to be 0.989 and 0.055 shown in figure 
6 and table no 13. 
2.  DRUG EXCIPIENT COMPATIBILITY 
Drug  and excipients interaction was checked out by comparing the FTIR spectra 
of pure drug Amoxicillin Trihydrate, diluted Potassium Clavulanate   FTIR spectra of the 
physical mixture of drug and excipients shown in Table No 14 - 17 and in Figure No                 
7 -10 
IR spectra result indicates that no significant difference in characteristic peak at 
wave numbers of the drug in presence of the excipients. From the results it can be 
concluded that drug and excipients are compatible. 
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2.    EVALUATION OF POWDER BLEND 
The results of the evaluation of the powder blend was shown in Table No:18. 
Angle of repose ranged from 25.11 to 29.11 and the compressibility index from 12-17. 
The LBD and TBD of the prepared granules ranged from   0.52 to 0.85 and 0.65 to 0.96 
respectively. Hausner’s ratio was found to be 1.2 or less than 1.2. The results of angle of 
Repose indicated good flow property of the granules and the value of the compressibility 
index further showed support for the flow property.  
3.   DISINTEGRATION TEST 
    The results of the disintegration test were shown in Table No: 19. Disintegration 
is the most important characteristic test of dispersible tablet, formulation F8 with 
Croscarmellose Sodium (CCS) 15% shows an excellent disintegration time of 55 seconds 
when compared with other formulations.  
4.  EVALUATION OF TABLETS 
The results of the evaluation of tablets were shown in Table No: 19. The thickness 
and average weight were found in the range of 3±0.1mm and 502 ±5 mg for all the 
formulation. In each formulation, weight variation was observed within the I.P limit ±5%. 
The hardness of different formulations was ranged from 5-7 kg /cm2. All the formulations 
exhibited less than 1% friability. The results were found to be within the content of 
uniformity limits (95 to 100.5%). It shows that the drug was uniformly distributed 
throughout the tablets.   The wetting time for all the formulation was found to be between 
73 to 123 seconds. All the formulations were passed the dispersibility test. 
5.  INVITRO DISSOLUTION STUDIES 
 The results of the in vitro dissolution studies were shown in table no 22-37 and in 
Figure no 11-26. In vitro dissolution test reveals the release increase from 89% to a 
maximum of almost 98% for Amoxicillin and from 89% to a maximum of almost 97% 
for Potassium Clavulanate. The release is in the following order of disintegrants 
Croscaramellose sodium > Crospovidone > Sodium Starch Glycolate > Maize starch. The 
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maximum in vitro dissolution was found to be with formulation F8.  The formulation 
with Sodium starch Glycolate 15% shows least in vitro dissolution of 89% and the 
formulation F8 Containing Croscarmellose Sodium were found to be contain maximum 
in vitro dissolution of 98%. It clearly shows that disintegrant (Croscarmellose Sodium 
15%) is the best when compared to other disintegrants. The reason may be high porous 
structure and water wicking mechanism into porous network of tablet hence increases in 
concentration of Croscarmellose Sodium accounts for rapid release (13, 16).  
 STABILITY STUDIES 
The results of the stability studies were shown in Table No 38.  The stability of 
optimized formulation F8 was monitored up to 4 weeks at 40°C ± 2°C and 25 °C±2°C 
temperature. Periodically (Initial and 4 weeks) samples were removed and evaluated by 
different parameters like Average Weight, Disintegration time (sec), Drug content (%), 
Hardness (kg/cm2), Friability (%) and Thickness. There were no major changes observed 
during stability of Amoxicillin and Potassium Clavulanate dispersible tablet ((F8).  
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Table No: 12 
Calibration Curve of Amoxicillin 
S.no Concentration Absorbance 
   1 0 0 
2 20 0.146 
3 40 0.248 
4 60 0.387 
5 80 0.466 
6 100 0.576 
  
 
 
 
 
 
                                                                Figure No 5  
Calibration Curve of Amoxicillin 
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Table No13 
Calibration Curve of Diluted Potassium Clavulanate 
 
S.No Concentration Absorbance 
1 0 0 
2 2 0.15 
3 4 0.24 
4 6 0.39 
5 8 0.453 
6 10 0.566 
 
 
                                                               
                                                                     
 
 
 
 
 
 
Figure No 6 
Calibration Curve of Diluted Potassium Clavulanate 
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 Figure 7 
  FTIR Spectrum of Amoxicillin Trihydrate 
 
Table No 14 
Ftir Interpretation of Amoxicillin Trihydrate 
 
Wave number in 
cm-1 
Assignment Mode of vibration 
1774 
1589 
1396 
3463 
C00H 
NH  
CN 
NH 
STRETCHING 
BENDING 
STRETCHING 
STRETCHING 
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Figure No 8 
FTIR Spectrum of Diluted Potassium Clavulanate 
 
                                                           Table No 15 
FTIR interpretation of Diluted Potassium Clavulanate 
                                    
Wave number in cm-1 Assignment Mode of vibration 
3976 
1791 
1596 
1386 
0H 
C=O 
C=C 
C=O 
STRETCHING 
STRETCHING 
STRETCHING 
STRETCHING 
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      Figure No 9 
FTIR Spectrum of Amoxicillin Trihydrate and Diluted   Potassium Clavulanate 
                                                     
 
Table No 16 
FTIR Interpretation of Amoxicillin Trihydrate and Diluted Potassium Clavulanate 
 
 
Wave number in 
cm-1 
Assignment Mode of vibration 
3970 
3463 
1791 
1766 
1619 
1603 
1401 
1387 
0H 
NH 
C=O 
C=C 
NH 
NH 
CN 
C-C 
STRETCHING 
STRETCHING 
STRETCHING 
STRETCHING 
BENDING 
BENDING 
STRETCHING 
STRETCHING 
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Figure No 10 
FTIR Spectrum of Optimized Formulation 
 
 
Table No 17 
Ftir Interpretation of Optimized Formulation 
Wave number in 
cm-1 
Assignment Mode of vibration 
3970 
3463 
1791 
1766 
1619 
1603 
1401 
1387 
0H 
NH 
C=O 
C=C 
NH 
NH 
CN 
C-C 
STRETCHING 
STRETCHING 
STRETCHING 
STRETCHING 
BENDING 
BENDING 
STRETCHING 
STRETCHING 
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Table No. 18  
Evaluation of Powder blend  
 
 
Sl 
No. Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
1 Angle of Repose 26.53
±0.22 
25.11
±0.25 
25.24
±0.24 
27.81
±0.12 
28.33
±0.20 
29.11
±0.27 
25.90
±0.32 
26.90
±0.25 
25.51
±0.27 
25.48
±0.25 
25.72
±0.24 
26.31
±0.25 
26.21
±0.28 
26.75
±0.29 
25.25
±0.23 
25.50
±0.27 
2 Bulk density 
(gm/ml) 
0.725
±0.32 
0.750
±0.36 
0.825
±0.33 
0.850
±0.32 
0.605
±0.13 
0.610
±0.35 
0.725
±0.36 
0.813
±0.33 
0.605
±0.38 
0.855
±0.33 
0.635
±0.38 
0.525
±0.36 
0.540
±0.32 
0.525
±0.34 
0.530
±0.36 
0.600
±0.37 
3 Tapped density 
(gm/ml) 
0.954
±0.13 
0.925
±0.30 
0.960
±0.23 
0.861
±0.34 
0.825
±0.32 
0.850
±0.43 
0.850
±0.37 
0.925
±0.35 
0.800
±0.38 
0.954
±0.32 
0.835
±0.36 
0.714
±0.36 
0.680
±0.38 
0.650
±0.32 
0.700
±0.30 
0.725
±0.35 
4 %Carr’s index 15.20
±0.23 
16.30
±0.32 
15.40
±0.33 
16.20
±0.35 
16.50
±0.36 
17.00
±0.38 
14.30
±0.35 
15.33
±0.32 
15.71
±0.38 
13.25
±0.37 
12.75
±0.53 
12.52
±0.36 
15.21
±0.23 
16.75
±0.30 
15.21
±0.37 
15.75
±0.34 
5 Hausner’s Ratio 1.115
±0.12 
1.033
±0.15 
1.166
±0.16 
1.012
±0.13 
1.163
±0.18 
1.193
±0.17 
1.172
±0.12 
1.137
±0.16 
1.122
±0.15 
1.102
±0.18 
1.114
±0.15 
1.160
±0.18 
1.159
±0.10 
1.138
±0.12 
1.120
±0.18 
1.008
±0.16 
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Table No. 19  
Evaluation of Physiochemical Properties of Tablet  
Sl 
No. 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
1 Average 
Weight (Mg) 
503± 
2 
502± 
3 
503± 
2 
502± 
2.5 
502± 
2.8 
501± 
3.5 
500± 
5 
500± 
4.5 
501± 
3.5 
503± 
1.5 
502± 
3.5 
502± 
2.5 
502± 
3.2 
504± 
3.5 
503± 
2.5 
504± 
2.5 
2 Thickness 
(mm) 
3± 
0.11 
3.2± 
0.12 
3.1± 
0.13 
3.0± 
0.15 
3.2± 
0.17 
3.5± 
0.12 
3.6± 
0.18 
3.7± 
0.16 
3.1± 
0.15 
3.8± 
0.17 
3.5± 
0.15 
3.9± 
0.18 
3.6± 
0.16 
3.2± 
0.12 
3.8± 
0.11 
3.3± 
0.12 
3 Hardness 
(Kg/Cm2) 
7± 
0.23 
6± 
0.12 
6.4± 
0.20 
5.0± 
0.22 
5± 
0.12 
5± 
0.25 
5± 
0.20 
5± 
0.28 
7.0± 
0.12 
6.4± 
0.23 
6.5± 
0.25 
7.0± 
0.28 
5.4± 
0.25 
6.5± 
0.28 
6.6± 
0.27 
5.4± 
0.29 
4 Friability (%) 0.8± 
0.06 
0.7± 
0.04 
0.6± 
0.05 
0.8± 
0.08 
0.52± 
0.07 
0.47± 
0.06 
0.48± 
0.04 
0.36± 
0.02 
0.62± 
0.06 
0.7± 
0.08 
0.9± 
0.06 
0.62±
0.06 
0.65± 
0.08 
0.82± 
0.06 
0.75± 
0.02 
0.64± 
0.05 
5 Wetting time 
(sec) 
117±
1  
123± 
2 
106± 
3  
100± 
1  
99± 
4  
93± 
2  
105± 
5  
92±3 89±4 85±2 79±6 73±4 105±
6 
95±5 90±6 84±5 
6 Disintegration 
Time (Secs) 
85± 
0.32 
80± 
0.23 
75± 
0.35 
80± 
0.32 
70± 
0.53 
76± 
0.32 
82± 
0.34 
55± 
0.36 
73± 
0.38 
79± 
0.36 
87± 
0.38 
98± 
0.39 
91± 
0.38 
73± 
0.23 
89± 
0.30 
82± 
0.33 
7 Uniformity of 
dispersion 
Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass 
8 Assay of 
Amoxicillin 
(%) 
96.24 96.50 97.25 96.54 98.98 98.53 98.79 99.00 98.21 98.35 98.50 98.72 96.23 96.52 96.70 97.52 
9 Assay of 
Clavulanic 
acid (%) 
96.10 96.20 96.00 96.34 98.78 98.32 98.60 98.87 98.00 98.15 98.30 98.52 96.00 96.42 96.50 97.00 
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                                                                                                 Table No: 20 
                                                        DISSOLUTION PROFILE OF FORMULATIONS (F1-F16) 
DISSOLUTION PROFILE - AMOXICILLIN 
Sl. 
No. 
TIME 
(SECONDS) 
(% of Drug release) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 5 35 37 39 41 48 45 46 47 45 45 46 47 43 43 44 46 
3 10 40 42 44 46 50 52 53 55 48 52 52 54 47 51 52 51 
4 15 52 55 57 59 64 64 65 67 62 62 63 65 59 62 62 65 
5 30 60 62 62 63 70 71 73 75 68 70 70 73 65 65 64 65 
6 60 70 73 75 77 85 87 83 86 78 78 80 82 75 75 77 80 
7 180 80 80 79 80 92 92 89 95 86 88 86 91 80 80 79 81 
8 300 82 82 81 85 93 94 90 95 89 90 87 93 85 85 83 85 
9 600 85 86 84 87 95 95 93 97 90 90 90 93 87 87 86 88 
10 900 87 88 89 90 97 97 97 98 95 95 96 96 89 89 90 92 
 
F1-F4=Maize Starch, F5-F8=CCS, F9-F12=Crospovidone, F13-F16= Sodium Starch Glycolate. 
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Table No: 21 
Dissolution profile of formulation F1-F16 
DISSOLUTION PROFILE – Potassium Clavulanate  
Sl. 
No. 
Time 
(Seconds) 
                                                             (% of Drug release)    
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 5 28 32 35 39 40 42 44 44 39 42 44 44 37 42 44 43 
3 10 35 37 42 44 48 46 50 50 47 50 52 50 47 50 50 48 
4 15 49 48 54 55 62 63 60 64 60 61 58 63 55 61 55 63 
5 30 57 56 60 60 67 69 67 70 65 65 66 70 60 63 63 64 
6 60 68 64 70 72 80 83 80 82 75 75 78 80 72 73 72 75 
7 180 75 75 74 77 90 85 82 90 80 80 80 85 75 75 75 78 
8 300 80 80 78 79 92 90 88 93 89 88 87 90 85 84 80 80 
9 600 85 81 82 85 95 94 92 95 90 89 88 91 86 86 84 85 
10 900 86 87 85 89 97 96 95 97 92 91 95 93 87 87 88 90 
 
F1-F4=Maize Starch, F5-F8=CCS, F9-F12=Crospovidone, F13-F16= Sodium Starch Glycolate. 
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Table No. 22 
Invitro Dissolution Profile of Formulation F1 Starch 5% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 35 28 
10 40 35 
15 52 49 
30 60 57 
60 70 68 
180 80 75 
300 82 80 
600 85 85 
900 87 86 
                    
 
Figure No 11  
Invitro Dissolution Profile of Formulation f1 starch 5% 
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Table No 23 
Invitro Dissolution Profile of Formulation F2 Starch 10% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 37 32 
10 42 37 
15 55 48 
30 62 56 
60 73 64 
180 80 75 
300 82 80 
600 86 81 
900 88 87 
 
 
 
Figure No 12 
Invitro Dissolution Profile of Formulation F2 Starch 10% 
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Table No 24 
Invitro Dissolution Profile of Formulation F3 Starch 12.5% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 39 35 
10 44 42 
15 57 54 
30 62 60 
60 75 70 
180 79 74 
300 81 78 
600 84 82 
900 89 85 
 
 
Figure No 13 
Invitro Dissolution Profile of Formulation f3 starch 12.5% 
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Table No 25  
Invitro Dissolution Profile of Formulation F4 starch 15% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 41 39 
10 46 44 
15 59 55 
30 63 60 
60 77 72 
180 80 77 
300 85 79 
600 87 85 
900 90 89 
 
 
Figure No 14  
Invitro Dissolution Profile of Formulation F4 Starch 12.5% 
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Table No 26 
Invitro Dissolution Profile of Formulation F5 CCS 5% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 48 40 
10 50 48 
15 64 62 
30 70 67 
60 85 80 
180 92 90 
300 93 92 
600 95 95 
900 97 97 
 
 
Figure No 15  
Invitro Dissolution Profile of Formulation F5 CCS 5% 
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Table No 27 
Invitro Dissolution Profile of Formulation F6 CCS 10% 
Time in Secs Amoxicillin Clavulanic acid 
0 0 0 
5 45 42 
10 52 46 
15 64 63 
30 71 69 
60 87 83 
180 92 85 
300 94 90 
600 95 94 
900 97 96 
 
 
 
 
Figure No. 16 
Invitro Dissolution Profile of formulation F6 CCS 10% 
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                                            Table No 28 
Invitro Dissolution  Profile of  Formulation F7 CCS 12.5 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 46 44 
10 53 50 
15 65 60 
30 73 67 
60 83 80 
180 89 82 
300 90 88 
600 93 92 
900 97 95 
 
 
  
Figure No 17 
Invitro Dissolution Profile of Formulation F7 CCS 12.5% 
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Table No 29  
Invitro  Dissolution  Profile of  Formulation F8 CCS 15% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 47 44 
10 55 50 
15 67 64 
30 75 70 
60 86 82 
180 95 90 
300 95 93 
600 97 95 
900 98 97 
  
 
  
Figure No 18  
Invitro Dissolution Profile of Formulation F8 CCS 15% 
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Table No 30 
Invitro  Dissolution Profile of  Formulation F9 CP5% 
Time in Secs Amoxicillin Clavulanic acid 
0 0 0 
5 45 39 
10 48 47 
15 62 60 
30 68 65 
60 78 75 
180 86 80 
300 89 89 
600 90 90 
900 95 92 
  
 
 
Figure No 19  
Invitro Dissolution Profile of Formulation F9 Cp 5% 
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Table No 31 
Invitro  Dissolution  Profile of  Formulation F10 Cp10% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 45 42 
10 52 50 
15 62 61 
30 70 65 
60 78 75 
180 88 80 
300 90 88 
600 90 89 
900 95 91 
 
  
 
Figure No 20 
Invitro Dissolution Profile of Formulation F9 Cp 10% 
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Table no 32 
Invitro  Dissolution Profile of  Formulation F11 cp12.5% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 46 44 
10 52 52 
15 63 58 
30 70 66 
60 80 78 
180 86 80 
300 87 87 
600 90 88 
900 96 95 
 
 
 
Figure No 21  
Invitro Dissolution Profile Profile of Formulation F11 Cp 12.5% 
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Table No 33 
Invitro  Dissolution  Profile of  Formulation F12 Cp15% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 47 44 
10 54 50 
15 65 63 
30 73 70 
60 82 80 
180 91 85 
300 93 90 
600 93 91 
900 96 93 
 
 
 
Figure No 22 
Invitro Dissolution Profile of Formulation f12 cp 15% 
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Table No. 34 
Invitro  Dissolution  Profile of  Formulation F13 SSG 5% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 43 37 
10 47 47 
15 59 55 
30 65 60 
60 75 72 
180 80 75 
300 85 85 
600 87 86 
900 89 87 
 
  
 
Figure No 23  
Invitro Dissolution Profile of Formulation F13 SSG 5% 
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Table No 35 
Invitro  Dissolution  Profile of  Formulation F14 SSG 10% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 43 42 
10 51 50 
15 62 61 
30 65 63 
60 75 73 
180 80 75 
300 85 84 
600 87 86 
900 89 87 
 
 
Figure no 24 
Invitro Dissolution Profile of Formulation F14 SSG 10% 
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Table No 36 
Invitro  Dissolution  Profile of  Formulation F15 SSG12.5% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 44 44 
10 52 50 
15 62 55 
30 64 63 
60 77 72 
180 79 75 
300 83 80 
600 86 84 
900 90 88 
   
 
Figure No 25  
Invitro Dissolution Profile of Formulation F15 SSG 12.5% 
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Table No 37  
Invitro  Dissolution  Profile of  Formulation F16 SSG 15% 
Time in secs Amoxicillin Clavulanic acid 
0 0 0 
5 46 43 
10 51 48 
15 65 63 
30 65 64 
60 80 75 
180 81 78 
300 85 80 
600 88 85 
900 92 90 
  
 
Figure No 26:  
Invitro Dissolution Profile of Formulation F16 SSG 15% 
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Table No. 38 
STABILITY REPORT 
                          
CONDITION Relative 
Humidity 
PERIOD 
(weeks) 
Colour Average 
wt (mg) 
Hardness(Kg/cm2) Friability 
(%) 
Disintegration 
time 
Thickness
(mm) 
Assay 
amox 
(%) 
Assay 
Clav 
(%) 
25 0 C  ± 2 0 C
 
60% RH 
± 5% RH  
0 White 500±5 5±0.5(Kg/cm2) 0.36±0.05 55±5 sec 3±0.1 99.00% 98.87% 
4 White 499±4 4.5±0.3(Kg/cm2) 0.30±0.5 55±2 sec 3±0.2 97.78% 97.00% 
40 C  ± 
2C 
 
75% RH 
± 5% RH 
0 White 500±5 5±0.5(Kg/cm2) 0.36±0.05 55±6 sec 3±0.1 99.00% 98.87% 
4 white 498±4 4.5±0.4(Kg/cm2) 0.32±0.05 55±4 sec    3±0.3 96.20% 96.31% 
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10. CONCLUSION 
The amoxicillin and potassium clavulanate dispersible tablets have been developed 
with direct compression method. The sixteen various compositions of formulations were 
prepared using Maize Starch, Sodium Starch Glycolate, Crospovidone, Croscarmellose 
sodium as a disintegrants. The powder blend were subject to various physical characteristics 
tests such as bulk density, tapped density, Hausner’s ratio, compressibility index and core 
tablets were evaluated for weight variation, hardness, thickness, disintegration time and the 
results were found within specification. In-vitro dissolution profile of sixteen formulations 
was carried out by using four disintegrants like Maize Starch, Sodium starch Glycolate, 
Crospovidone and Croscarmellose sodium. The In-vitro dissolution profile of F8 using 
croscarmellose sodium (15%) was found maximum release when compared to other 
formulations. The optimized batch tablets were packed in ALU-ALU pack and performed 
stability studies at 40°C/75% RH.  All the results were found to be satisfactory.  Sweetening 
agent i.e Aspartame and flavouring agent i.e strawberry flavour were used to increase 
palatability of the dispersible tablet.  Hence the designed and developed formula of 
combination of Amoxicillin and Potassium Clavulanate dispersible tablets could be used as 
alternate dosage form. 
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11. SUMMARY 
 
The present work is aimed to develop a stable formulation of preferred combination 
of two antibiotics -Amoxicillin and Potassium Clavulanate by using various disintegrants.  
Amoxicillin and Potassium Clavulanate dispersible tablets were prepared by direct 
compression method using different disintegrants i.e. Croscarmellose, Crospovidone Maize 
starch and Sodium Starch Glycolate. Aspartame as a sweetener and strawberry flavor were 
used to increase palatability.  The Powder blends were subject to various physical 
characteristics test such as bulk density, tapped density, Hausner’s ratio and Compressibility 
Index. The prepared tablets were evaluated for hardness, friability, Disintegration time and 
Wetting time and in vitro drug release.  Amoxicillin and Potassium Clavulanate dispersible 
tablets were found to be of good quality fulfilling all the requirements for dispersible tablets. 
The results indicated that concentration of Crospovidone, Croscarmellose sodium, Sodium 
starch glycolate and maize starch significantly affected the release property of the drug.  
Croscarmellose sodium showed high disintegration time as compared to batches prepared 
from Maize starch, Sodium starch Glycolate and Crospovidone. The In-vitro dissolution 
profile of F8 using Croscarmellose Sodium (15%) was found better than all other 
formulations. The optimized batch tablets were packed in ALU-ALU pack and performed 
stability studies at 40°C/75%RH.  There is no change in the physiochemical properties of the 
tablet during the stability period. Hence the designed and developed formula of combination 
of Amoxicillin and Potassium Clavulanate dispersible tablets was found suitable alternate 
dosage form. 
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